DMID Protocol 19- [ADDRESS_521221]  2023 
 ______________________________________________________________________________________________________  
DMID/NIAID/NIH    CONFIDENTIAL  [ADDRESS_521222] Neisseria gonorrhoeae following 
meningococcal immunization in healthy young adults 
DMID Protocol Number:  19-0015 
DMID Funding Mechanism s: Vaccine and Treatment Evaluation Unit (VTEU)  (Protocol 
Development);  Infectious Diseases Clinical Research Consortium (IDCRC)  (Protocol 
Implementation, Analysis, and Closeout) 
IND Sponsor: Division of Microbiology and Infectious Diseases , NIAID, NIH, DHHS  
Lea
d Principal Investigator:  [INVESTIGATOR_413603] K. Phadke MD  
DMID Clinical Project Manager: Peter Wolff  
Vers
ion Number:  7.[ADDRESS_521223]  2023 
 ______________________________________________________________________________________________________  
DMID/NIAID/NIH    CONFIDENTIAL  2 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018STATEMENT OF ASSURANCE  
Each Institution will hold a current Federal Wide Assurance (FWA) issued by [CONTACT_12198] (OHRP) for federally -funded human subjects research.  Each FWA 
will designate at least one Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) registered with OHRP, for which the research will be reviewed and approved by [CONTACT_5040]/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated 
under an FWA may include an institution’s IRB/IEC, an independent IRB/IEC, or an IRB/IEC of another institution  after establishing a written agreement with that other institution.  
DMID Protocol 19- [ADDRESS_521224]  2023 
 ______________________________________________________________________________________________________  
DMID/NIAID/NIH    CONFIDENTIAL  3 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018STATEMENT  OF COMPLIANCE  
The study trial will be carried out in accordance with Good Clinical Practice (GCP)  and as 
required by [CONTACT_716]: 
•[LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of Human
Subjects
•Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50(Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_51343]), 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21CFR Part 312 (Investigational New Drug Application), 21 CFR 812 (Investigational
Device Exemptions)
•International Conference on Harmonis ation : Good Clinical Practice ( ICH E6 ); 62 Federal
Register [ZIP_CODE] (1997); and future revisions
•Belmont Report: Ethical Principles an d Guidelines for the Protection of Human Subjects
of Research, Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research
•National Institutes of Health (NIH) Office of Extramural Research, Research InvolvingHuman Subjects, as applicable
•National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award ,
as applicable
•Applicable Federal, State, and Local Regulations and Guidance
DMID Protocol 19- [ADDRESS_521225]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      4 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  SIGNATURE [CONTACT_413670], including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations and ICH E6 Good Clini cal Practice (GCP)  guidelines. 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when necessary to protect the safety, rights, or welfare of subjects.  
Site Investigator  Signature: 
 
[INVESTIGATOR_14586]:  Date:   
 Varun K. Phadke MD 
Associate Professor of Medicine, Division of 
Infectious Diseases  
Emory University Vaccine and Treatment Evaluation Unit (VTEU)  
The Hope Clinic of the Emory Vaccine Center    
  
DMID Protocol 19- [ADDRESS_521226]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521227]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      6 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  4 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  .........................................[ADDRESS_521228] Storage and Stability .........................................................................36  
4.2 Acquisition/Distribution  .............................................................................................36  
4.3 Dosage/Regimen, Preparation, Dispensing and Administration of Study 
Intervention/Investigational Product.........................................................................36  
4.4 Accountability Procedures for the Study Intervention/Investigational Product(s) .....[ADDRESS_521229] Replacement  ......................................................................................44  
5.2.3  Study Termination .........................................................................................44  
6 STUDY PROCEDURES  ......................................................................................................45  
6.1 Screening  ....................................................................................................................45  
6.1.1  Visit 00A, Day -56 to -1 for subjects in the no biopsy cohort / -[ADDRESS_521230] Screen, Clinic Visit  ....................................45  
6.1.2  Visit 00B, Day -7 to -1 for subjects in the no biopsy cohort / -34 to -28 for 
subjects in the biopsy cohort, 2nd Screen, Clinic Visit (optional) .................[ADDRESS_521231]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      7 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  6.3.1  Visit 02, Day 8 (±1 day), Clinic Visit ............................................................50  
6.3.2  Visit 03, Day 15 (±1 day), Clinic Visit ..........................................................51  
6.3.3  Visit 04, Day 29 (±1 day), Second Vaccination, Clinic Visit ........................51  
6.3.4  Visit 05, Day 36 (±1 day), Clinic Visit ..........................................................53  
6.3.5  Visit 06, Day 43 (±3 days), Rectal Mucosal Biopsy, Clinic Visit .................53  
6.3.6  Visit 06P, Day 44 (+1 day), Telephone Visit .................................................54  
6.3.7  Visit 07, Day 57 (±1 day), Clinic Visit ..........................................................55  
6.3.8  Visit 08, Final Study Visit, Day 181 (±7 days), Clinic Visit .........................56  
6.3.9  Early Termination Visit .................................................................................57  
6.4 Unscheduled Study Visits ...........................................................................................57  
6.5 Protocol Deviations ....................................................................................................58  
7 DESCRIPTION OF CLINICAL AND LABORATORY EVALUATIONS  .......................59  
7.1 Clinical Evaluations  ....................................................................................................59  
7.1.1  Research Procedures  ......................................................................................60  
7.1.2  Assessment of Concomitant Medications/Treatments other than Study 
Product ...........................................................................................................61  
7.2 Laboratory Evaluations ...............................................................................................62  
7.2.1  Clinical Laboratory Evaluations ....................................................................62  
7.2.2  Research Assays  .............................................................................................63  
[IP_ADDRESS]  Antibody assays ................................................................................63  
[IP_ADDRESS]  Cell-mediated immunity assays  ........................................................64  
[IP_ADDRESS]  Bacterial adhesion assay  ...................................................................64  
[IP_ADDRESS]  Laboratory Specimen Preparation, Handling, and Storage ...............64  
[IP_ADDRESS]  Laboratory Specimen Shippi[INVESTIGATOR_007] ........................................................65  
8 ASSESSMENT OF SAFETY  ...............................................................................................66  
8.1 Assessing and Recording Safety Parameters  ..............................................................66  
8.1.1  Adverse Events  ..............................................................................................66  
[IP_ADDRESS]  Adverse Events Grading ...................................................................[ADDRESS_521232]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      8 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  8.1.2  Reactogenicity  ................................................................................................68  
8.1.3  Serious Adverse Events .................................................................................68  
8.2 Specification of Safety Parameters  .............................................................................69  
8.2.1  Solicited Events  .............................................................................................69  
8.2.2  Unsolicited Events .........................................................................................70  
8.2.3  Medically -Attended Adverse Events (MAAEs) ............................................[ADDRESS_521233] Values or 
Abnormal Clinical Findings......................................................................................72  
8.6 Halting Rules  ..............................................................................................................73  
8.6.1  Study Halting Criteria  ....................................................................................73  
8.6.2  Individual Halting Criteria  .............................................................................73  
8.7 Safety Oversight .........................................................................................................74  
8.7.1  Independent Safety Monitor (ISM) ................................................................74  
8.7.2  Safety Monitoring C ommittee (SMC)  ...........................................................[ADDRESS_521234]/Independent Ethics Committee  ......................................76  
9.2 Informed Consent Process ..........................................................................................76  
9.3 Consent for Future Use of Stored Specimens and Data .............................................78  
9.4 Exclusion of Women, Minorities, and Children (Special Populations) ......................[ADDRESS_521235]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      9 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  10 STATISTICAL CONSIDERATIONS  .................................................................................82  
10.1  Study Hypotheses .......................................................................................................82  
10.2  Sample Size Considerations  .......................................................................................82  
10.3  Treatment Assignment Procedures  .............................................................................84  
10.3.1  Randomization Procedures ............................................................................84  
10.3.2  Masking Procedures .......................................................................................84  
10.4  Planned Interim Analyses ...........................................................................................85  
10.4.1  Interim Safety Review  ...................................................................................85  
10.4.2  Interim Immunogenicity Review  ...................................................................85  
10.5  Final Analysis Plan  .....................................................................................................85  
10.5.1  Analysis Populations ......................................................................................86  
[IP_ADDRESS]  Immunogenicity Population ..............................................................86  
[IP_ADDRESS]  Safety Population ..............................................................................[ADDRESS_521236] KEEPI[INVESTIGATOR_1645]  ................................................................91  
13.1  Data Management Responsibilities  ............................................................................91  
13.2  Data Coordinating Center/Biostatistician Responsibilities  ........................................[ADDRESS_521237]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521238]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521239] OF TABLES  
Table 1:  Treatment Arm Goals*  ...............................................................................................20  
Table 2:  95% Confidence Intervals for GMTs and GMT Ratios across a range of 
Sample Sizes and Antigens .........................................................................................[ADDRESS_521240]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521241] OF ABBREVIATIONS  
4CMenB  Bexsero® or multi -component meningococcal serogroup B 
vaccine  
ACIP  Advisory Committee on Immunization Practices  
AE Adverse Event/Adverse Experience  
aPTT  Activated Partial Thromboplastin Time  
BLA  Biologics License Applications  
BMI  Body Mass Index  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CIOMS  Council for International Organizations of Medical Sciences  
CMS  Clinical Material Services  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -[ADDRESS_521242]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521243]  
FHbp  Factor H Binding Protein  
FWA  Federal  Wide Assurance  
GC Neisseria gonorrhoeae  
GCP  Good Clinical Practice  
GMFR  Geometric Mean Fold Rise  
GMT  Geometric Mean Titer  
HEENT  Head/Ear/Eyes/Nose/Throat  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
IATA  International Air Transport Association  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICS Intracellular Cytokine Staining  
IDCRC  Infectious Diseases Clinical Research Consortium  
IDE Investigational Device Exemption  
IDES  Internet Data Entry System  
IEC Independent or Institutional Ethics Committee  
DMID Protocol 19- [ADDRESS_521244]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521245]  
ISM Independent Safety Monitor  
IUD Intrauterine Device  
JAMA  Journal of the American Medical Association  
LLC  Limited Liability Corporation  
MAAEs  Medically -Attended Adverse Events  
MBC  Memory B Cell  
MedDRA Medical Dictionary for Regulatory Activities  
MeNZB  New Zealand Meningococcal Group B Vaccine  
mL Milliliter  
mm Millimeter   
MM Medical Monitor  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NAAT  Nucleic Acid Amplification Test  
NadA  Neisserial Adhesion A  
NDA  New Drug Application  
NEJM  New England Journal of Medicine  
NHBA  Neisserial Heparin Binding Antigen  
DMID Protocol 19- [ADDRESS_521246]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      15 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
NSAID  Non-Steroidal Anti -Inflammatory Drug  
OER  Office of Extramural Research  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
OMV  Outer Membrane Vesicle  
PBMC  Peripheral Blood Mononuclear Cell  
PBS Phosphate -Buffered Saline  
PHI Protected Health Information  
PI [INVESTIGATOR_413604]/Serious Adverse Experience  
SAP Statistical Analysis Plan  
SBA  Serum Bactericidal Antibody  
SDCC  Statistical and Data Coordinating Center  
SMA  Secondary Medical Assessor  
DMID Protocol 19- [ADDRESS_521247]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521248]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      17 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  PROTOCOL SUMMARY  
 
Title:  Mucosal immune responses against Neisseria gonorrhoeae  
following meningococcal immunization in healthy young adults 
Design of the Study:  
 This is a mechanistic clinical trial to assess the systemic and 
mucosal immunogenicity of the multicomponent meningococcal 
serogroup B vaccine (4CMenB or Bexsero®) (group 1, approximately 40 subjects ) against N. gonorrhoeae (GC), using a 
placebo  vaccine ( normal saline ) as a comparator (group 2, 
approximately 10 subjects ). 
Study Phase:  2 
Study Population:  This trial will enroll  approximately  50 (maximum of 60 subjects) 
healthy male and non-pregnant female subjects aged 18 to 49 years, and will be conducted in the US 
Number of Sites:  1 (Emory University VTEU)   
Description of Study 
Product or Intervention:  The active product will be Bexsero® (4CM enB), a FDA -
approved multi-component meningococcal serogroup B vaccine that contains outer membrane vesicles ( OMVs ) containing PorA 
serosubtype P1.4, as well as three recombinant protein antigens (neisserial adhesion A [NadA], factor H binding protein [FHbp] fusion protein, and neisserial heparin binding antigen [NHBA] fusion protein). 4CMenB is presented as a single-dose prefilled syringe that is administered intramuscularly on a 2 dose (0.5-Milliliter (mL ) each) schedule, with the second dose to be given 
[ADDRESS_521249] will be a normal saline placebo.  
Study Objectives : 
 Primary:  
• To characterize the rectal mucosal  Immunoglobin G 
(IgG) antibody response to GC elicited by [CONTACT_941] 4CMenB 
DMID Protocol 19- [ADDRESS_521250]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      18 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  vaccine as compared with the placebo  vaccine in healthy 
adult subjects. 
Secondary: 
• To characterize the serum IgG antibody response to GC 
elicited by [CONTACT_941] 4CMenB vaccine as compared with the 
placebo  vaccine in healthy adult subjects. 
• To assess the safety and  reactogenicity of 4CMenB in 
healthy adult subjects. 
• Exploratory: 
• To characterize the vaginal mucosal IgG antibody 
response to GC  elicited by [CONTACT_941] 4CMenB vaccine as 
compared with the placebo vaccine in healthy adult 
subjects.  
• To characterize the oropharyngeal mucosal IgG antibody 
response to GC  elicited by [CONTACT_941] 4CMenB vaccine as 
compared with the placebo vaccine in healthy adult 
subjects.  
• To characterize the serum Immunoglobin A ( IgA) 
antibody response to GC  elicited by [CONTACT_941] 4CMenB vaccine 
as compared with the placebo  vaccine in healthy adult 
subjects.  
• To characterize the mucosal IgA antibody response to 
GC elicited by [CONTACT_941] 4CMenB vaccine as compared with 
the placebo  vaccine in healthy adult subjects.  
• To characterize the systemic B cell responses to GC 
antigens elicited by 4CMenB vaccine as compared with the placebo  vaccine in healthy adult subjects.  
• To characterize the systemic T cell responses to GC  
antigens elicited by 4CMenB vaccine as compared with the placebo  vaccine in healthy adult subjects.  
DMID Protocol 19- [ADDRESS_521251]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      19 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • To characteri ze the mucosal T cell responses to GC 
antigens elicited by 4CMenB vaccine as compared with 
the placebo  vaccine in healthy adult subjects.  
• To characterize the serum bactericidal antibody responses 
to GC elicited by 4CMenB vaccine as compared with the 
placebo  vaccine in healthy adult subjects. 
• To evaluate the impact of 4CMenB vaccine-induced 
antibodies on gonococcal adhesion to human cervical 
cells.  
• To characterize immune responses to N. meningitidis 
elicited by [CONTACT_941] 4CMenB vaccine as compared with the placebo vaccine in healthy adult subjects for use as controls. 
Duration of Individual 
Subject Participation:  The duration of each subject’s participation is approximately [ADDRESS_521252]/Last Study Day:  Approximately [ADDRESS_521253]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      20 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Table 1: Treatment Arm  Goals* 
 Rectal Mucosal Biopsy Cohort 
(N=20) No Rectal Mucosal Biopsy Cohort 
(N=30) Total  
Vaccine  Male Non-pregnant 
Female  Male Non-Pregnant 
Female   
4CMenB  8 8 12 12 40 
Placebo  2 2 3 3 10 
 
*As noted in the study design, t his trial will enroll approximately 50 (maximum of 60 subjects) 
healthy male and non-pregnant female subjects aged [ADDRESS_521254]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      21 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  1 KEY ROLES  
Lead Principal 
Investigator:                                    
 
  
 
    [INVESTIGATOR_413603] K. Phadke, MD  
Associate Professor of Medicine, Division of Infectious 
Diseases  
Emory University Vaccine and Treatment Evaluation Unit (VTEU)  
The Hope Clinic of the Emory Vaccine Center  
[ADDRESS_521255],  
Decatur, GA [ZIP_CODE] 
Phone:  
Fax:  
Email:  
DMID Clinical Project 
Manager:  Peter A. Wolff , MHA  
DMID, NIAID, NIH  
[ADDRESS_521256] 
Bethesda, MD, [ZIP_CODE]  
Email:  
  
Statistical and Data 
Coordinating Center:  
 The Emmes Company, LLC  
[ADDRESS_521257],  
Rockville, MD [ZIP_CODE] Phone:  
Email:  

DMID Protocol 19- [ADDRESS_521258]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      22 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  IDCRC Protocol 
Management : 
 FHI [ADDRESS_521259],  
Durham, NC [ZIP_CODE] 
Phone:  

DMID Protocol 19- [ADDRESS_521260]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      23 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  2 BACKGROUND AND SCIENTIFIC RATIONALE  
2.1 Background  
Gonorrhea is a sexually transmitted infection (STI) caused by [CONTACT_413624] -negative diplococcus 
GC. It causes urethritis and cervicitis in sexually active men and women respectively, and in 
women can lead to upper genital tract disease (i.e. , pelvic inflammatory disease ( PID)), which is 
a risk factor for ectopic pregnancy and infertility. Extragenital infections of other mucosal sites 
(e.g., rectum and pharynx) are also possible, as are invasive infections (i.e., di sseminated 
gonococcal infection, or DGI) such as gonococcal arthritis/dermatitis syndrome, septic arthritis, and endocarditis. Finally, perinatally acquired infection – which typi[INVESTIGATOR_413605] – can cause sight -threateni ng conjunctivitis (ophthalmia 
neonatorum). 
In [ADDRESS_521261] -line therapy – ceftriaxone and azithromycin – have emerged.[ADDRESS_521262] been l argely unsuccessful. 
Recently, a retrospective case-control study in New Zealand demonstrated 31% (95% confidence interval (CI), 21-39) effectiveness of an OMV meningococcal group B vaccine (MeNZB) against incident gonorrhea.
4 The same group of investigators also reported 24% (95% CI, 1-42) vaccine 
effectiveness against hospi[INVESTIGATOR_413606].[ADDRESS_521263] been used successfully to control epi[INVESTIGATOR_413607] 
N. meningitidis  serogroup B.8 These vaccines elicit serum bactericidal antibody (SBA) responses 
directed primarily against meningococcal strain -specific porin protein, PorA.[ADDRESS_521264]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      24 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  A four component meningococcal serogroup B vaccine (Bexsero® or 4CMenB) was recently 
licensed for  use in the [LOCATION_002] and was given a category B recommendation by [CONTACT_413625] (ACIP) for use in adolescents and young adults up to 25 years of age.
10 Bexsero includes OMVs containing PorA serosubtype P1.4, as well as 
three recombinant protein antigens (neisserial adhesion A [NadA], factor H binding protein [FHbp] fusion protein, and neisserial heparin binding antigen [NHBA] fusion protein).
[ADDRESS_521265] of 4CMenB on immunologic responses at the 
human mucosal surfaces where GC is typi[INVESTIGATOR_413608] (urethra, rectum, cervix, and 
pharynx).  
2.2 Scientific  Rationale  
2.2.1 Purpose of Study  
This is a  mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the 
multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero®) against GC , using 
a placebo  vaccine ( normal saline ) as a comparator , in healthy young adults. 
4CMenB is licensed for use in those aged 10- [ADDRESS_521266]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      25 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  2.2.2 Study Population 
The study population will include approximately 50 males and  non-pregnant females, 18 to 49 
years of age, inclusive, who are in good health and meet all eligibility criteria. 
Subjects will be recruited from the community at large and enrolled at 1 VTEU site (Hope 
Clinic , Emory VTEU ). 
This age range was selected to represent the population with the highest incidence of gonorrhea2 
therefore children are excluded from this study. There are no plans currently to include children in future studies of mucosal immune responses to GC  after meningococcal immunization.  
2.3 Potential Risks and Benefits 
2.3.1 Potential Risks  
The potential risks of participating in this trial are those related to having venous blood drawn, the intramuscular injections, possible reactions to the 4CMenB or placebo  vaccines, undergoing 
oropharyngeal, vaginal and rectal mucosal sampling, and breach of confidentiality. 
Blood draw and I
 ntramuscular ( IM) injection  
Drawing blood may cause transient discomfort and fainting and lead to or exacerbate iron 
deficiency in those who are not anemic. Fainting is usually transient and managed by [CONTACT_413626]/her legs. Bruising at the blood draw site may occur but can be prevented or lessened by [CONTACT_413627] s ite for a few minutes after the  
blood is taken.  IM injection may also cause transient discomfort and fainting. Drawing blood and IM injection may cause infection. The use of aseptic (sterile) technique will make infection at the  
site where blood will be drawn or where the study vaccination will be given extremely unlikely. 
Bexsero ® (
4CMenB) 
Bexsero ® was licensed by [CONTACT_413628] B in 2005 and is approved for use in individuals aged 10 
through 25 years. 
A comprehensive description of the risks of adverse events ( AEs) are described in the package 
insert.[ADDRESS_521267] common (frequency ≥ 10%) solicited adv erse reactions observed in clinical 
trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), 
headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%). 
DMID Protocol 19- [ADDRESS_521268]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521269] marketing experience, lymphadenopathy been reported after receiving Bexsero.  Since 
this was voluntarily reported from a population of uncertain size, the incidence rate cannot be estimated.  
There are limited safety data for 4CMenB in adults over age 25 years. Although the vaccine is licensed fo r use in individuals aged 10 through 25 years, the ACIP has noted that there are no 
theoretical differences in safety for persons aged >25 years compared with those aged 10 –25 
years, thus the ACIP supports the routine use of MenB vaccines in persons aged ≥ [ADDRESS_521270] one dose of 4CMenB with a median age of 20 years (range 16-65 years).
16 In this analysis, 8.4% of 
vaccinated individuals reported any AE, with the most common AEs being pain in the injected arm (10%), fever (9%), headache (5%), nausea (4%), and fatigue (4%). A total of 54 individuals 
(0.3%) experienced a Serious Adverse Event ( SAE ), only three of which were suspected to be 
related to the 4CMenB.  In one phase 1 study of healthy adults aged 18- 40 years
17 and three phase 
2 studies of laboratory workers (age range 18 -65 years)18-20 receiving 4CMenB vaccination , the 
vaccine was well -tolerated and there were no SAEs.   
Oropharyngeal mucosal secretion sampling  
Oropharyngeal secretion sampling may cause transient discomfort. Participants will be asked to 
stop some activities before these samples are collected, including oral sex, or use of certain oral 
or inhaled immunomodulatory agents – such as corticosteroids  – which may be inconvenient. 
Vaginal mucosal secretion sampling  
Vaginal mucosal secretion sampling may cause anxiety, trans ient discomfort, and 
embarrassment. Participants will be asked to stop some activities before these samples are 
collected, including vaginal sex, or use of anything in or around their vagina – such as tampons, spermicide, lubricants, or medications (e.g., topi[INVESTIGATOR_106754]) – which may be inconvenient. 
Rectal m u
cosal secretion sampling  
Rectal mucosal secretion sampling may cause anxiety, transient discomfort, and embarrassment. 
Participants will be asked to stop some activities before these samples a re collected, including 
receptive anal intercourse, or insertion of anything into their anus – such as cleaning products, lubricant, enemas, or douches (including water) – which may be inconvenient. 
DMID Protocol 19- [ADDRESS_521271]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521272]. Kelley’s team has performed >300 similar procedures for other IRB approved protocols with zero complications.   
All procedures will utilize disposable rigid sigmoidoscopes, forceps, and guides to reduce risk of 
infection and obviate the need for instrument sterilization between participants.  To minimize risks, rigid proctoscopy, rather than flexible sigmoidoscopy or full colonoscopy, will be used in this study and the number of biopsies taken will be limited to 12.  Colonoscopy has been shown to be associated with a still low, but significantly greater risk of complications than rectosigmoidoscopy.
23 The frequency of serious complications after flexible sigmoidoscopy is 
extremely low and complications from rigid sigmoidoscopy are presumably even lower, but unknown.  In two large studies including a combined 144,832 clinically indicated procedures, the incidence of serious complications ranged from 0.06 to 0.8% utilizing flexible sigmoidoscopy.
23, 
[ADDRESS_521273] 
available data on the risk of multiple biopsie s comes from studies of dysplasia surveillance 
among patients with long-standing inflammatory bowel disease, in whom large numbers of “blind” biopsies are obtained throughout the colon for early detection of malignant transformation. In two such studies including a combined 3,011 procedures and a median of eight and 17 biopsies, respectively, there was only one serious complication, for an incidence of approximately 0.33%.
25, 26 In a study of subjects undergoing endoscopic procedures exclusively 
for research purposes, including 64 flexible sigmoidoscopi[INVESTIGATOR_15128] a mean of 25 biopsies obtained from the rectosigmoid, there were no major complications. Thirteen subjects experienced minor symptoms (self -limited bleeding and pain), which were not related to the number of biopsies.
27  
A summary of procedures across several Microbicide Trial Network (an NIH -funded, 
international network designed to develop topi[INVESTIGATOR_413609] 
(HIV) prevention) was published in 2017.[ADDRESS_521274]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      28 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  sigmoidscopy procedures with >15,000 biopsy collection from 278 research participants. Many 
participants underwent multiple procedures (median 3 procedures). There were no SAEs , and an 
AE related to sigmoidoscopy was reported in 1.6% of procedures. Eight of the 16 related AEs reported were ab dominal pain, flatulence, bleeding, diarrhea, and bloating. Fourteen of the 16 
related AEs were grade 1 and 2/16 were grade 2; median time to resolution was 1 day. The authors concluded that repeated intestinal mucosal biopsies for research purposes are safe. Thus, 
based on the available data, the risk of serious complications from the proposed study 
procedures, even with up to 10 biopsy specimens, is expected to be very low (<1:5000).  
There is theoretical risk of increased acquisition of HIV or other infection if a study participant is 
exposed soon after the rectal biopsy procedure (i.e. while the mucosal surface is damaged).  
Therefore, study subjects will be counseled not to engage in anal intercourse for 1 week after the 
rectal biopsy procedure.  
Biologic samples will be coded with a unique identifier prior to processing and storage for 
immunologic assays.  Therefore, lab personnel will be unable to link specimens with 
participants.  Only the PI [INVESTIGATOR_413610]-investigators/study personnel will be able to access information to identify specimens of individual participants. 
Breach of Confidentiality  
Subjects will be asked to provide protected  health information (PHI). All attempts will be made 
to keep this PHI confidential within the limits of the law. However, there is a chance that 
unauthorized persons will see a subject’s PHI. All records will be kept in a locked file cabinet or 
maintained in a locked room at the site. Electronic files will be password protected. Only people 
who are involved in the conduct, oversight, monitoring, or auditing of this trial will be allowed access to this PHI. Any publications from this trial will not use information that will identify  
subjects by [CONTACT_2300]. Organizations that may inspect and/or copy research records maintained at the site for quality assurance (QA) and data analysis include groups such as NIAID (or its designee) and FDA.  
A description of this trial will be available on http://www.ClinicalTrials.gov, as required by [CONTACT_122797]. This web site will not include information that can identify subjects. At most, this web site  
will include a summary of the results.  
There may be other unknown risks, discomforts, or side effects. 
 
DMID Protocol 19- [ADDRESS_521275]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      29 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  2.3.2 Potential Benefits  
For subjects assigned to the Bexsero® group of the study, this  meningococcal vaccine is  known 
to elicit protective antibodies  against N. meningitidis serogroup B in adults aged 10-[ADDRESS_521276]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      30 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  3 STUDY DESIGN, OBJECTIVES  AND ENDPOINTS OR 
OUTCOME MEASURES  
3.1 Study Design Description  
This is a single- center phase 2 double blinded mechanistic clinical trial to assess the systemic 
and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine 
(4CMenB or Bexsero®) against GC , using a placebo  vaccine ( normal saline ) as a comparator . 
This trial will enroll approxima tely 50 healthy male and non-pregnant female subjects aged 18 to 
49 years, inclusive, who meet all eligibility criteria.  Subjects will be randomized 4:1 to one of 
two treatment groups. Group 1 (approximate N=40) will receive two doses of 4CMenB on Day 1 
and Day 29. Group 2 ( approximate N=10) will receive two  placebo injections on Day 1 and Day 
29. The goal will be to ensure adequate representation of subjects by [CONTACT_413629] 
(Table 1)  
Vaccine preparation and administration will be unblinded. Only pharmacy personnel, the Emmes 
unblinded team and an unblinded vaccinator will have access to the study codes, and all other 
study personnel will be blinded. Subjects will be followed through [ADDRESS_521277] vaccination (Day 181).  
All subjects will undergo  sampling  of mucosal secretions for testing for antibodies against GC . 
Male subjects will undergo oropharyngeal and rectal mucosal samplin g, and f emale subjects will 
undergo oropharyngeal, vaginal and rectal mucosal sampling. A subset of subjects in each treatment group (N=16 in Group 1, N=4 in Group 2) will undergo rectal mucosal biopsy at two time points (baseline and following the second vaccination) for assessment of tissue GC  specific 
cellular  responses. The goal will be to ensure adequate representation of subjects by [CONTACT_413630] ( Table 1).  
This trial is expected to take approximately 14 months to complete, from initiation through availability of a final report on the primary outcomes of mucosal antibody responses and the secondary outcomes of serum antibody responses and safety outcomes related to mucosal sampling procedures and 4CMenB vaccination. For additional details on study procedures and evaluations and study schedule by [CONTACT_319650]/days, see Sections  6, 7, and 8 and well as 
Appendices Ap pendix A  and Appendix B . 
Schematic of Study Design: See Table 1. 
DMID Protocol 19- [ADDRESS_521278]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      31 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  3.2 Study Objectives  
3.2.1 Primary   
• To characterize the rectal mucosal IgG antibody response to GC  elicited by [CONTACT_941] 4CMenB 
vaccine as compared with the placebo  vaccine ( normal saline ) in healthy adult subjects. 
3.2.2 Secondary  
• To characterize the serum IgG antibody response to GC  elicited by [CONTACT_941] 4CMenB vaccine 
as compared with the placebo  vaccine in healthy adult subjects. 
• To assess the saf ety and reactogenicity of 4CMenB in healthy adult subjects. 
3.2.3 Exploratory  
• To characterize the vaginal mucosal IgG antibody response to GC  elicited by [CONTACT_941] 
4CMenB vaccine as compared with the placebo  vaccine in healthy adult subjects.  
• To characterize the oropharyngeal mucosal IgG antibody response to GC  elicited by [CONTACT_941] 
4CMenB vaccine as compared with the placebo  vaccine in healthy adult subjects.  
• To characterize the serum IgA antibody response to GC  elicited by [CONTACT_941] 4CMenB vaccine 
as compared with the placebo  vaccine in healthy adult subjects. 
• To characterize the mucosal IgA antibody response to  GC elicited by [CONTACT_941] 4CMenB 
vaccine as compared with the placebo  vaccine in healthy adult subjects.  
• To characterize the systemic B cell responses to GC antigens elicited by 4CMenB 
vaccine as compared with the placebo  vaccine in healthy adult subjects. 
• To characterize the systemic T cell responses to GC  antigens elicited by 4CMenB 
vaccine as compared with placebo  vaccine in healthy adult subjects. 
• To characterize the mucosal T cell responses to GC  antigens elicited by 4CMenB vaccine 
as compared with the placebo  vaccine in healthy adult subjects. 
• To characterize the serum bactericidal antibody responses to GC  elicited by 4CMenB 
vaccine as compared with the placebo  vaccine in healthy adult subjects. 
• To evaluate the impact of 4CMenB vaccine-induced antibodies on gonococcal adhesion 
to human cervical cells.  
DMID Protocol 19- [ADDRESS_521279]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      32 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • To characterize immune  responses to N. meningitidis  elicited by [CONTACT_941] 4CMenB vaccine as 
compared with the placebo vaccine in healthy adult subjects  for use as controls. 
3.3 Study Endpoints or Outcome Measures 
3.3.1 Primary  
• Rectal mucosal IgG concentrations (geometric mean titers, GMT) against GC  OMV 
antigens at Day 1, 29, 43, 57, and 181 in each treatment group 
3.3.2 Secondary  
• Serum IgG  concentrations (GMT) against GC  OMV antigens at Day 1, 29, 43, 57, and 
181 in each treatment group  
• Frequency and severity of any AE related to 4CMenB immunization through the end of 
the study. 
• Frequency of SAEs through the end of the study. 
3.3.3 Exploratory  
• Rectal mucosal IgG concentrations (GMT) against GC  antigens before and after 
vaccinat ion in each treatment group 
• Serum IgG concentrations (GMT) against GC  antigens before and after vaccination in 
each treatment group  
• Vaginal mucosal IgG concentrations  geometric mean titer (GMT) against GC antigens 
before and after vaccination  in female subjects in each treatment group  
• Oropharyngeal mucosal IgG concentrations (GMT) against GC  antigens before and after 
vaccination  in each treatment groupSerum IgA concentrations (GMT) against  GC 
antigens before and after vaccination  in each treatment group 
• Rectal mucosal IgA concentrations  (GMT) against GC  antigens before and after 
vaccination in each treatment group 
• Vaginal mucosal IgA concentrations (GMT) against GC  antigens before and after 
vaccination in female subjects in each treatment group 
• Oropharyngeal mucosal IgA concentrations (GMT) against GC  antigens before and after 
vaccination in each treatment group 
DMID Protocol 19- [ADDRESS_521280]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      33 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Frequencies and function of memory B cells specific for antigens from GC  before and 
after vaccination  by [CONTACT_413631]. 
• Frequencies and function of peripheral blood T cells specific for antigens from GC  before 
and after vaccination  by [CONTACT_413631].  
• Frequencies, p henotype, and function of peripheral blood CD4+ T cell s specific for 
antigen s from  GC based on cytokine profile before and after vaccination  by [CONTACT_413632]. 
• Frequencies, phenotype, and function of peripheral blood CD8+ T cells specific for 
antigens from GC  based on cytokine profile befor e and after vaccination  by [CONTACT_413632]. 
• Frequencies, phenotype, and function of rectal mucosal CD4+ T cells specific for 
antigens from GC  based on cytokine profile before and after vaccination  by [CONTACT_413632]. 
• Frequencies, phenotype, and function of rectal mucosal CD8+ T cells specific for antigens from GC  based on cytokine profile before and after vaccination  by [CONTACT_413632]. 
• Serum bactericidal antibody titers against GC   before and after vaccination in each 
treatment group. 
• Percent inhibition of gonococcal adhesion to human cervical cell line (ME180) by 
[CONTACT_413633] 43 in each treatment group. 
• Serum IgG concentrations (GMT) against N. meningitidis  antigens before and after 
vaccination  in each treatment group 
• Frequencies and function of memory B cells specific for antigens from N. meningitidis  
before and after vaccination  by [CONTACT_413631]. 
• Frequencies and function of peripheral blood T cells specific for antigens from N. meningitidis  before and after vaccination  by [CONTACT_413631].  
• Frequencies, phenotype, and function of peripheral blood CD4+ T cells specific for antigens from N. meningitidis  based on cytokine profile before and after vaccination  by 
[CONTACT_413634]. 
DMID Protocol 19- [ADDRESS_521281]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      34 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Frequencies, phenotype, and function of peripheral blood CD8+ T cells specific for 
antigens from N. meningitidis  based on cytokine profile before and after vaccination  by 
[CONTACT_413634]. 
DMID Protocol 19- [ADDRESS_521282]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      35 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  4 STUDY INTERVENTION/INVESTIGATIONAL 
PRODUCT 
4.[ADDRESS_521283] Description  
Bexsero®11: Active Product 
Each 0.5-mL dose of Bexsero ® (4CMenB) is formulated to contain 50 micrograms each of 
recombinant proteins NadA, NHBA, and fHbp, 25 micrograms of OMV, 1.5 mg aluminum 
hydroxide (0.519 mg of Al3+), 3.125 mg sodium chloride, 0.776 mg histidine, and 10 mg sucrose at pH 6.4 – 6.7. The NadA component is a fragment of the full-length protein derived from N. meningitidis  strain 2996 (peptide 8 variant 2/3). The NHBA component is a recombinant 
fusion protein comprised of NHBA (peptide 2) and accessory protein 953 derived from N. meningitidis  strains NZ98/254 and 2996, respectively. The fHbp component is a recombinant 
fusion protein comprised of fHbp (variant 1.1) and the accessory protein 936 derived from N. meningitidis  strains MC58 and 2996, respectively. These 3 recombinant proteins are individually 
produced in Escherichia coli  and purified through a series of column chromatography steps. The 
OMV antigenic component is produced by [CONTACT_413635] N. meningitidis  strain NZ98/254 
(expressing outer membrane protein PorA serosubtype P1.4), followed by [CONTACT_413636], which also mediates vesicle formation. The antigens are adsorbed onto aluminum hydroxide. Each dose contains less than 0.01 micrograms kanamycin (by [CONTACT_413637]) 
Placebo  
The placebo is 0.9% Sodium Chloride, USP injection . 
 
4.1.1 Formulation, Packaging, and Labeling 
Bexsero ® : Active Product  
Bexsero ® (4CMenB) is a sterile, white, opalescent, suspension for intramuscular injection. 
4CMenB is supplied as a 0.5-mL suspension in a glass prefilled syringe (packaged without 
needles). The tip caps of the prefilled syringes contain natural rubber latex; the plungers are not made with natural rubber latex . 
The study product will be labeled according to manufacturer or regulatory specifications and include the s tatement “Caution: New Drug – Limited by [CONTACT_12201].”  
DMID Protocol 19- [ADDRESS_521284]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      36 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Placebo  
Placebo will be supplied as 0.9% Sodium Chloride Injection, USP which is a colorless, sterile, 
nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains supplied chloride 9 mg. It contains no bacteriostatic, antimicrobial agent, or added buffer and is supplied only in single-dose containers. The placebo, 0.9% Sodium Chloride, contains no preservatives. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 5.3 [4.5 to 7.0]). 
 4.1.[ADDRESS_521285] Storage and Stability  
Bexsero ®
 : Active Product  
Bexsero ® (4CMenB) must be stored  between 2°C to 8°C (36°F to 46°F). Do not freeze. Do not 
use if the vaccine has been frozen. Protect from light. 
Placebo  
0.9% Sodium Chloride, USP injection must be stored at 20ºC to 25ºC (68°F to 77ºF) [See USP 
Controlled Room Temperature; excursions between 15°C and 30°C (59°F and 86°F) are permitted]. See protocol- specific manual of procedures ( MOP ) for further instructions.  
4.2 Acquisition/Distribution  
Bexsero ®: Active Product  
4CMenB will be provided by [CONTACT_413638] (CMS, Fisher BioServices).  
Placebo  
Normal saline will be used as the placeb o and will be provided by [CONTACT_413639] (Fisher 
BioServices ). 
4.3 Dosage /Regimen , Preparation , Dispensing  and Administration of 
Study Intervention/Investigational Product 
Bexsero ® (4CMenB): Active Product 
Bexsero ® (4CMenB) will be administered as a 2 dose series (0. 5-mL each) with the second dose 
given [ADDRESS_521286] dose (Day 1 and Day 29) in participants randomized to Group 1. 
DMID Protocol 19- [ADDRESS_521287]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      37 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Shake the syringe immediately before use to form a homogeneous suspension. Do not use the 
vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is found. 
Bexsero ® will be administered as a 0.5 -mL intramuscular injection into the deltoid muscle of the 
upper arm. The vaccine dose will be administered within 30 minutes following removal from the 
refrigerator.  
Placebo  
The placebo will be administered as a 2-dose series (0.5- mL each)  with the second dose given [ADDRESS_521288] dose (Day 1 and Day 29) in participants randomized to Group 2.  
Gently invert the normal saline vial 5 to 7 times. Using aseptic technique, puncture the septum 
top of the saline vial with a 1 -inch, 23- or 25 -gauge disposable, sterile needle attached to a 1 -mL 
disposable, sterile syringe. Withdraw 0.5 mL from the saline vial. The prepared saline dose in the 
syringe will be allowed to store at room temperature and administered within 30 minutes. The 
dose will be admin istered IM over the deltoid region of the preferred arm. 
Syringes for both Bexsero and placebo will be overlayed  with a blinding tape and flagged  
(wrapped)  with  a prescription label. Labeling specifics will be referenced in the MOP.  Labeled 
syringes will be provided to the unblinded vaccine administrator. The unblinded vaccine administrator will be credentialed to administer vaccines but will not be involved in study -related 
assessments, subject contact, or data collection following vaccination.  
4.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s) 
Study vaccines will be stored and shipped from the DMID contract CMS  to the Clinical Sites. 
Once received, vaccines  will be stored in and dispensed by [CONTACT_156979]. DMID 
will determine the disposition of unused product.  
The FDA requires accounting for the disposition of all investigational products. The Investigator 
is responsible for ensuring that a current record of product disposition is maintained and product is dispensed only at an official study site by [CONTACT_202413]. Records of product disposition, as required by [CONTACT_81918], consist of the date received, date administered, quantity administered, and the subject number to whom the drug was administered.  
DMID Protocol 19- [ADDRESS_521289]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521290] to inspection by a regulatory agency (e.g., FDA) at any time. An assigned Study Monitor will review the pharmacy records. 
Unused investigational product syringes will be stored at [ADDRESS_521291]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      39 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  5 SELECTION OF SUBJECTS AND STUDY 
ENROLLMENT AND WITHDRAWAL  
Subjects will be recruited through: posting of IRB-approved flyers on the Emory University 
campus; use of social media, list serves (such as CDC, Emory University, Emory Vaccine Center, and Vaccine Dinner Club), and clinical trial recruitment websites; a HIPAA -compliant 
clinical trials database to identify subjects of previous studies at the Hope Clinic who have agreed to future contact; presentations by [CONTACT_413640]; and volunteer word-of-mouth. 
If subjects are agreeable and interested, they will be screened initially over the phone for general 
eligibility criteria and their PHI will be saved in a locked cabinet in a secure office of the study coordinator/recruiter. When appropriate, an appointment at the Hope Clinic is then scheduled for an in-person clinic visit. Research staff will then obtain written consent per the standard 
informed consent process before conducting protocol- specific screening activities.  
This study will enroll both male and non-pregnant female subjects. The goal will be to ensure 
approximately adequate representation  of subjects by [CONTACT_413641] ( Table 1 ). 
To facilitate this, enrollment will be stratified by [CONTACT_413642] . Enrollment of 
subjects by [CONTACT_78471] “cohort” (either “biopsy” or “no biopsy”) will be based on  the numbers listed 
in Table 1 , and all subjects will be randomized 4:[ADDRESS_521292] be confirmed by a study clinician licensed to make medical diagnoses  and listed on the Form FDA 1572 as the site principal investigator (PI) or sub-
investigator. No exemptions are granted on Subject Inclusion/Exclusion Criteria in DMID -
sponsored studies. Questions about eligibility will be directed toward the DMID Medical Officer. 
5.[ADDRESS_521293] meet all the following inclusion criteria to be eligible for this trial: 
1. Must b e aged 18 -49 years old (inclusive) at the time of vaccination. 
2. Must be able to provide written informed consent. 
3. Must have a body mass index (BMI) ≥18.5 and <35.0 kg/m2 
DMID Protocol 19- [ADDRESS_521294]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521295] be in good health based on physical examination, vital signs*, medical history, 
safety labs ** (as applicable to the rectal biopsy and no biopsy cohorts ) and the 
investigator’s clinical judgment.  
*Vital signs must be within the normal ranges in Appendix C  If a subject has elevated 
systolic or diastolic blood pressure, subject may rest for 10 minutes in a quiet room and the blood pressure may be retaken. 
**Safety labs must be within the normal ranges in Appendix C , and the normal ranges will 
be those used by [CONTACT_413643] . 
5. For female subjects only: If a female participant is of childbearing potential*, she must 
use contraception** from [ADDRESS_521296] administration through the end of study participation. 
*A woman is considered of childbearing potential unless post-menopausal (defined as history of 
≥1 year of spontaneous amenorrhea), or permanently surgically sterilize d (bilateral 
oophorectomy, salpi[INVESTIGATOR_1656], hysterectomy). 
**Acceptable methods of contraception include: abstinence or no sex with a male, monogamous 
relationship with a man who had a vasectomy at least [ADDRESS_521297] study vaccine, prescription oral contraceptives, intrauterine device (IUD), birth control implants or injections, contraceptive patch, vaginal ring, condoms and diaphragms /cervical cap with 
spermicide (“double barrier” method)  
6. Must be available and willing to participate for the duration of this trial.  
7. Willing to provide mucosal samples: vaginal secretions for women and oropharyngeal and rectal secretions  for men and women. 
8. For the rectal biopsy cohort only, willing to provide rectal biopsies. 
 
5.1.[ADDRESS_521298] Exclusion Criteria  
Subjects meeti ng any of the following exclusion criteria at baseline will be excluded from study 
participation: 
1. Has ever been diagnosed with meningococcal infection or gonococcal infection at any 
anatomic  site.  
2. Has ever received any serogroup B meningococcal vaccine. 
DMID Protocol 19- [ADDRESS_521299]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521300] result for STI (including GC/ Chlamydia trachomatis  (CT), Rapid 
Plasma Reagin ( RPR) and HIV) at screening *. 
*Female subjects will also be tested for Trichomonas at screening. 
4. Any history of Chlamydia trachomatis or syphilis infection at any body site in the 
preceding 12 months. 
5. Has known allergy or history of anaphylaxis or other serious adverse reaction to a 
vaccine or vaccine products.  
6. Has severe allergy or anaphylaxis to latex. 
7. Has an acute illness or temperature ≥38.0°C on Day 1*. 
*Subjects with fever or acute illness on the day of vaccination may be re-assessed and enrolled if 
healthy or only minor residual symptoms remain within 3 days. 
8. Has a history of a bleeding disorder, or is taking chronic anti-coagulant (e.g. warfarin, 
direct thrombin inhibitors, heparin products, etc.), anti- platelet, or Non -Steroidal Anti-
Inflammatory Drug ( NSAID ) therapy. 
9. Has history of autoimmune disease, or clinically significant cardiac, pulmonary, gastrointestinal, hepatic, rheumatologic, or renal disease by [CONTACT_212384]. 
10. Has history of active malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure*. 
*Subjects with a history of skin cancer must not be vaccinated at the previous tumor site. 
11. Has known or suspected congenital or acquired immunodeficiency, or recent history or current use of immunosuppressive therapy*. 
*Anti- cancer chemotherapy or ra diation therapy within the preceding 3 years, or long- term (≥2 
weeks within the previous 3 months) systemic corticosteroid therapy (at a dosage of ≥0.5 mg/kg/day). Intranasal or topi[INVESTIGATOR_413611] (or equivalent) are allowed. 
12. Is post- organ and/or stem cell  transplant, whether or not on chronic immunosuppressive 
therapy. 
13. Had major surgery (per the investigator’s judgment) within [ADDRESS_521301]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      42 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  14. Has history of diabetes* mellitus type 1 or type 2, including cases controlled with diet 
alone*. 
*History of isolated gestational diabetes is not an exclusion criterion. 
15. Received live attenuated vaccines from [ADDRESS_521302] vaccination until 30 days after second vaccination. 
16. Received killed or inactivated vac cines* from [ADDRESS_521303] vaccination until 14 
days after second vaccination.  
*For inactivated influenza vaccine, from [ADDRESS_521304].* 
 *COVID -[ADDRESS_521305] vaccination or plans to receive any experimental therapeutic agents during this trial  except for EUA 
COVID-19 therapy.* 
*Only exclusionary if, in the opi[INVESTIGATOR_871], they would interfere with safety or 
endpoint assessment. 
19. Is currently participating or plans to participate in another clinical study which would 
involve receipt of an investigational product or undergoing a procedure*. 
*Only exclusionary if, in the opi[INVESTIGATOR_871], they would interfere with safety o r 
endpoint assessment. 
20. Received blood products or immunoglobulin in the [ADDRESS_521306]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521307] be recorded in the c ase report forms (CRFs).  
The reasons for subject withdrawal or discontinuation of study product, might include, but are not limited to the following: 
• Subject no longer meets eligibility criteria  
• Subject meets individual halting criteria (reference to sect ion 8.6.2) 
• Subject becomes noncompliant 
• Medical disease or condition, or new clinical finding(s) for which continued 
participation, in the opi[INVESTIGATOR_202378], interfere with the subject's successful completion of this study, or interfere with the evaluation of responses 
• Subject lost to follow -up 
• Subject becomes pregnant, if applicable 
• Determ ined by a physi cian’s discretion to require additional therapy not indicated in the 
protocol to ensure subject’s health and well- being (or treatment failure, if applicable)  
DMID Protocol 19- [ADDRESS_521308]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      44 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  The investigator should be explicit regarding study follow-up (e.g., safety follow -up) that might 
be carried out despi[INVESTIGATOR_122748].  If the subject 
consents, every attempt will be made to follow all AEs through resolution.  The procedures that collect safety data for the purposes of resea rch must be inclusive in the original informed consent 
or the investigator may seek subsequent informed consent using an IRB/IEC-approved consent form with the revised procedures. 
The investigator will inform the subject that already collected data will be  retained and analyzed 
even if the subject withdraws from this study.  5.2.[ADDRESS_521309] to follow-up after signing 
the informed consent form (ICF) and administration of the study product may  be replaced  at the 
investigator’s discretion .  Subjects who withdraw, or are withdrawn from this study, or are lost to 
follow-up after signing the ICF but before administration of the study product may be replaced at 
the investigator’s discretion.   
5.2.3 Study Termination  
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure 
appropriate therapy or follow-up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB/IEC.  
DMID Protocol 19- [ADDRESS_521310]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      45 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  6 STUDY PROCEDURES 
6.1 Screening  
6.1.1 Visit 00A, Day -56 to -1 for subjects in the no biopsy cohort / -[ADDRESS_521311] screening visit. 
• Begin the informed consent process. Provide subjects with a description of this trial 
(purpose and study procedures) and ask them to read the ICF. Provide an opportunity to 
the potential subject to ask questions. If she/he wishes to proceed with participation, the ICF should be signed before performing any screening procedures 
• Review eligibility criteria.  
• Interview subjects to collect demographics, medical history, sexual history, vaccination 
history, and pre-study medication use. Interview of subjects is sufficient for obtaining 
medical history. Solicitation of med ical records from the subject’s primary care provider 
is not required. 
• Review subjects’ concomitant medications taken within 30 days before signing the ICF. 
• Obtain vital signs, including oral temperature, pulse, and blood pressure to assure 
eligibility.  
• Measure height and weight and calculate BMI.  
• Perform a physical examination including the following organs and organ systems: general appearance, head/eyes/ears/nose/throat (HEENT), neck, lungs, heart, abdomen, 
extremities, musculoskeletal, lymph nodes, skin, and nervous system. Genital and rectal 
exams will be performed at the investigator’s discretion. All physical exams will be done by a clinician licensed to make medical diagnoses and listed on Form FDA 1572 as site PI [INVESTIGATOR_11637]- investigator  
• Collect venous blood for RPR and HIV-1/2 antibody testing. 
• During screening  for the rectal biopsy cohort only, collect venous blood for complete 
blood count (White Blood Count ( WBC ), hemoglobin, Platelet Count ( PLT)), 
prothrombin time (PT) and activated partial thrombopla stin time (aPTT)  
DMID Protocol 19- [ADDRESS_521312]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      46 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Collect urine for pregnancy test from all female subjects of childbearing potential. 
• Collect pharyngeal and rectal swabs for nucleic acid amplification testing (NAAT) for 
GC and CT 
• Collect urine for NAAT for GC/CT from male subjects  
• Collec t a self -collected vaginal swab for NAAT for GC/CT /Trichomonas from female 
subjects  
• The overall eligibility of the subject to participate in this trial will be assessed once all screening test values and results of any other required evaluations are availa ble. Subjects 
who qualify for inclusion will be contact[CONTACT_413644] 28 days. 
• Subjects who qualify for inclusion in the rectal biopsy cohort will be instructed to abstain 
from receptive anal  intercourse or insertion of anything into their anus, for at least 2 days 
prior to  the baseline rectal mucosal biopsy visit 
• Subjects who qualify for inclusion will be instructed to abstain from receptive anal and/or vaginal intercourse, insertion of anything into their vagina and/or anus, or oral sex for at 
least 2 days prior to the enrollment/first vaccination visit  
 
6.1.2 Visit 00B, Day -7 to -1 for subjects in the no biopsy cohort / -34 to -28 for 
subjects in the biopsy cohort , 2nd Screen, Clinic Visit (optio nal) 
This screening visit will only occur to repeat a screening assessment whose initial result is thought to be temporary). The following activities will be performed at the 2
nd screening visit if 
it occurs.  
• Review eligibility criteria, including results of available clinical screening lab 
evaluations. 
• Review medical history and any updates obtained by [CONTACT_413645] (Visit 00A) to assure continued eligibility. 
• Review interim sexual history to identify any new sexual partne rs since the last screening 
visit 
• Review all concomitant medications recorded on the appropriate Electronic Case Report 
Form  (eCRF ). 
DMID Protocol 19- [ADDRESS_521313]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      47 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Obtain vital signs including oral temperature, blood pressure, and pulse , if needed . 
• Measure height and weight and calculate BMI, if needed . 
• Perform a targeted physical examination, if needed. 
• Collect blood and urine for safety labs, if needed 
• Subjects who qualify for inclusion in the rectal biopsy cohort will be instructed to abstain 
from receptive anal intercourse or  insertion of anything into their anus, for at least [ADDRESS_521314] for subjects being enrolled in the rectal biopsy cohort. The 
following activities will be performed at Visit 00C.  
• Ensure participant is safe to proceed with biopsy procedure, including results of all 
clinical screening lab evaluations*. 
 *If the initial safety labs are >28 days old, these tests will need to be repeated and results 
obtained before rectal mucosal biopsy (see Section 7.2).  
• Review medical history and any updates obtained by [CONTACT_413646] (Visit 00A or, if performed, Visit 00B) to assure the participant is safe to 
proceed with biopsy procedure. 
• Review interim sexual history to identify any new sexual partners since the last screening visit 
• Review all concomit ant medications and recent (within 28 days) vaccinations with 
subjects before the first vaccination for accuracy and completeness. Any new medications taken since the last screening visit (Visit 00A or, if performed, Visit 00B) will be recorded on the appropriate eCRF  and reviewed to assure the participant is safe to 
proceed with biopsy procedure. 
• Assess all AE/SAEs from the biopsy procedure and record them on the appropriate Electronic Case Report Form ( eCRF ). 
DMID Protocol 19- [ADDRESS_521315]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      48 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Obtain vital signs including oral temperature, blood pressure, and pulse to assure the 
participant is safe to proceed with biopsy procedure. Vital signs obtained on the day of 
biopsy will not be considered "screening", nor used for determining eligibility. 
• Perform a targeted physical examination as needed before the biopsy procedure , if 
indicated based on review of complete medical history and updates obtained by [CONTACT_413646] (Visit 00A or, if performed, Visit 00B). 
• Perform rigid sigmoidoscopy and c ollect rectal mucosal biopsy samples for immunologic 
assays as described in the Schedule of Events ( Appendix A ) (for subjects in the mucosal 
biopsy subgroup). 
• Subjects will be counseled not to engage in anal intercourse for 1 week after the rectal biopsy procedure. 
• Subjects will be reminded to abstain from receptive anal and/or vaginal intercourse, 
insertion of anything into their vagina and/or anus, or oral sex for at least 2 days prior to 
the enrollment/first vaccination visit. 
 
6.1.[ADDRESS_521316] 24 -48 hours after the baseline rectal biopsy procedure only for subjects 
enrolled in the rectal biopsy cohort. The following activities will be performed at Visit 00 P. 
• Assess all AE/SAEs from the biopsy procedure and record them on the appropriate 
eCRF.  
• Subjects will be reminded not to engage in anal intercourse for 1 week after the rectal 
biopsy procedure. 
• Subjects will be reminded to abstain from receptive anal and/or vaginal intercourse, insertion of anything into their vagina and/or anus, or oral sex for at least 2 days prior to 
the enrollment/first vaccination visit.  
 
6.[ADDRESS_521317]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      49 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Reconfirm the subject’s willingness to participate before performing any study 
procedures, including their first vaccination. 
• Review eligibility criteria, including results of HIV , RPR, and STI screening lab 
evaluations, with subjects before the first vaccination to assure continued eligibility. 
• Review interim se xual history to identify any new sexual partners since the last screening 
visit. Subjects that report new sexual exposures should undergo repeat STI screening and 
enrollment should be deferred until results are available and assure continued eligibility. 
• Review medical history and any updates obtained by [CONTACT_413647] (Visit 00A or, if performed, Visits 00B and/or 00C) to assure continued 
eligibility.  
• Review all concomitant medications and recent (within 28 days) vaccinations with 
subjects before the first vaccination for accuracy and completeness. Any new medications 
taken since the last screening visit (Visit 00A or, if performed, Visit s 00B and/or 00C ) 
will be recorded on the appropriate eCRF  and assessed for co ntinued eligibility.  
• Review COVID -[ADDRESS_521318] 14 days out from any 
COVID-19 vaccine before receiving study vaccine. 
• Assess all AE/SAEs and record them on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse before the first 
vaccination. Perform a targeted physical examination as needed before the first 
vaccination, if indicated based on review of complete medical history and updates obtained by [CONTACT_413646] (Visit 00A or, if performed, Visit s 00B and/or 00C ). 
• Perform a urine pregnancy test within [ADDRESS_521319] vaccination . 
• Collect blood samples for baseline immunologic assays as described in the Schedule of 
Events ( Appendix A ) 
• Collect rectal and oropharyngeal mucosal secretion samples for immunologic assays as 
described in the Schedule of Events ( Appendix A ) 
• From female subjects, collect vaginal mucosal secretion samples for immunologic assays 
as described in the Schedule of Events ( Appendix A ) 
DMID Protocol 19- [ADDRESS_521320]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      50 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Subjects will be enrolled in Advantage eClinical  and randomly assigned before the first 
vaccination.  
• Perform pre -administration reactogenicity assessments before the first vaccination to 
establish baseline. Subjects will then receive a single dose of vaccine via IM injection 
into the deltoid muscle of the preferred arm. The site of injection (right or left arm) and time of administration will be recorded on the appropriate eCRF.  
• Observe subjects in the clinic for ≥ 15 minutes after vaccination to monitor for any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥[ADDRESS_521321] on the appropriate CRF.  
• Subjects will enter their reactogenicity information in a n electronic memory aid  (with a 
paper back up). Subjects will be provided a thermometer and  ruler and will record daily 
oral temperature, solicited injection site and systemic reactions, any unsolicited AEs, and concomitant medications. Subjects will have their electronic memory aid  reviewed  with 
them at their next study visit.  
 
6.3 Planned Study Visits  
6.3.1 Visit 02, Day 8 (± 1 day), Clinic Visit  
The following activities will be performed at Visit 02. 
• Obtain interim medical history  by [CONTACT_413648].  
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse, if indicated 
based on review of complete medical history. 
• A targeted physical examination will be performed, if needed, by a study clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Assess for reactogenicity phenomena through subject interview and review memory aid. 
DMID Protocol 19- [ADDRESS_521322]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      51 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Examine vaccination site for local reactions . 
• Collect bloo d samples for immunologic assays as described in the Schedule of Events 
(Appendix A ). 
 
6.3.2 Visit 03, Day 15 (± 1 day), Clinic Visit  
The following activities will be performed at Visit 03.  
• Obtain interim medical history  by [CONTACT_413648].  
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse, if indicated 
based on review of complete medical history. 
• A targeted physical examination will be performed, if needed, by a study clinician licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Collect blood samples for immun ologic assays as described in the Schedule of Events 
(Appendix A ) 
• Subjects will be instructed to abstain from receptive anal and/or vaginal intercourse, 
insertion of anything into their vagina and/or anus , or oral sex  for at least 2 days prior to 
the next study visit 
 
6.3.3 Visit 04, Day 29 (±1 day), Second Vaccination, Clinic Visit 
The following activities will be performed at Visit 04.  
• Obtain interim medical history  by [CONTACT_413648].  
• Review interim sexual history to identify any new sexual partners since the last screening 
visit 
• Record all concomitant medications on the appropriate eCRF . 
DMID Protocol 19- [ADDRESS_521323]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      52 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Review COVID -[ADDRESS_521324] 14 days out from any 
COVID-19 vaccine before receiving study vaccine. 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse. 
• A targeted physical examination will be performed, if needed, by a study clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Collect venous blood for RPR testing  
• Collect pharyngeal and rectal swabs for nucleic acid amplification testing (NAAT) for 
GC and CT 
• Collect urine for NAAT for GC/CT from male subjects  
• Collect a self -collected vaginal swab for NAAT for GC/CT from female subjects  
• Collect blood samples for immunologic assays as described in the Schedule of Events (Appendix A ) 
• Collect rectal and oropharyngeal mucosal secretion samples for immunologic assays as described in the Schedule of Events ( Appendix A ) 
• From female subjects, collect vaginal mucosal secretion samples for immunologic assays 
as described in the Schedule of Events ( Appendix A ) 
• Perform a urine pregnancy test within [ADDRESS_521325] be negative and known before second 
vaccination.  
• Perform pre -administration reactogenicity assessments before  the second vaccination to 
establish baseline. Subjects will then receive a single dose of vaccine via IM injection into the deltoid muscle of the preferred arm. The site of injection (right or left arm) and 
time of administration will be recorded on the a ppropriate eCRF . 
• Observe subjects in the clinic for ≥ 15 minutes after vaccination to monitor for any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥ [ADDRESS_521326]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      53 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Subjects will enter their reactogenicity information in an electronic memory aid  (with 
paper back up). Subjects will be provided a thermometer and ruler (if needed) and will 
record daily oral temperature, solicited injec tion site and systemic reactions, any 
unsolicited AEs, and concomitant medications. Subjects will have their electronic 
memory aid reviewed with them at their next study visit.  
 
6.3.4 Visit 05, Day 36 (± 1 day), Clinic Visit  
The following activities will be performed at Visit 0 5. 
• Obtain interim medical history  by [CONTACT_413648].  
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse, if indicated 
based on review of complete medical history. 
• A targeted physical examination will be performed, if needed, by a study clinician licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Assess for reactogenicity phenomena through subject interview and review memory aid 
• Examine vaccination site for local reactions  
• Collect blo od samples for immunologic assays as described in the Schedule of Events ( 0) 
• Subjects will be instructed to abstain from receptive anal and/or vaginal intercourse, 
insertion of anything into their vagina and/or anus , or oral sex  for at least 2 days prior to 
the next study visit 
 
6.3.5 Visit 0 6, Day 43 ( ±3 days ), Rectal Mucosal Biopsy, Clinic Visit  
The following activities will be performed at Visit 0 6. 
• Obtain  interim medical history  by [CONTACT_413648].  
DMID Protocol 19- [ADDRESS_521327]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      54 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Obtain interim sexual history to identify any new sexual partners since the start of the 
study and the second vaccination visit 
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse. 
• A targeted physical examination will be performed, if needed, by a study clinician licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• If indicated based on the subject’s interim sexual history: Collect pharyngeal and rectal 
swabs for NAAT for GC and CT, collect urine for NAAT for GC/CT from male subjects, 
and collect a self -collected vaginal swab for NAAT for GC/CT from female subjects  
• Collect blood samples for immunologic assays as described in the Schedule of Events 
(Appendix A ) 
• Collect rectal and oropharyngeal mucosal secretion samples for immunologic assays as 
described in the Schedule of Events ( Appendix A ) 
• From female subjects, collect vaginal mucosal secretion samples for immunologic assays 
as described in the Schedule of Events ( Appendix A ) 
• Perform rigid sigmoidoscopy and c ollect rectal mucosal biopsy samples for immunologic 
assays as described in the Schedule of Events ( Appendix A ) (for subjects in the mucosal 
biopsy subgroup) 
• Subjects will be counseled not to engage in anal intercourse for 1 week after the rectal biopsy procedure. 
• Subjects will be instructed to abstain from receptive anal and/or vaginal intercourse, insertion of anything into their vagina and/or anus , or oral sex  for at least 2 days prior to 
the next study visit 
 
6.3.6 Visit 06 P, Day 44 (+1 day), Telephone Visit 
This visit will take place [ADDRESS_521328]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      55 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Assess all AE/SAEs from the biopsy procedure and record them on the appropriate 
eCRF.  
• Subjects will be reminded not to engage in anal intercourse for 1 week after the rectal 
biopsy procedure. 
• Subjects will be reminded to abstain from receptive anal and/or vaginal intercourse, insertion of anything into their vagina and/or anus, or oral sex for at least 2 days prior to 
the next study visit.  
 
6.3.7 Visit 0 7, Day 57 (± 1 day), Clinic Visit  
The following activities will be performed at Visit 0 7. 
• Obtain interim medical history  by [CONTACT_413648].  
• Review interim sexual history to identify any new sexual partners since the last screening 
visit 
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse, if indicated based on review of complete medical history. 
• A targeted physical examination will be performed, if needed, by a study clinician licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Collect blood samples for immunologic assays as described in the Schedule of Events 
(Appendix A ) 
• Collect rectal and oropharyngeal mucosal secretion samples for immunologic assays as described in the Schedule of Events ( Appendix A ) 
• From female subjects, collect vaginal mucosal secretion samples for immunologic assays as described in the Schedule of Events ( Appendix A ) 
DMID Protocol 19- [ADDRESS_521329]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      56 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Subjects will be instructed to abstain from receptive anal and/or vaginal intercourse, 
insertion of anything into their vagina and/or anus, or oral sex for at least 2 days prior to 
the next study visit 
 
6.3.8 Visit 0 8, Final Study Visit , Day 181 (± 7 days), Clinic Visit  
The following activities will be performed at Visit 0 8. 
• Obtain interim medical history  by [CONTACT_413648].  
• Obtain interim sexual history to identify any new sexual partners since the last study visit 
• Record  all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse, if indicated 
based on review of complete medical history. 
• A targeted physical examination will be performed, if needed, by a study clinician licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI [INVESTIGATOR_11637]-
investigator, if indicated based on review of complete medical history. 
• Collect venous blood for RPR and HIV-1/2 antibody testing 
• Collect pharyngeal and rectal swabs for NAAT for GC and CT  
• Collect urine for NAAT for GC/CT from male subjects  
• Collect a self -collected vaginal swab for NAAT for GC/CT from female subjects  
• Collect blood samples for immunologic assays as described in the Schedule of Events (Appendix A ) 
• Collect rectal and oropharyngeal mucosal secretion samples for immunologic assays as described in the Schedule of Events ( Appendix A ) 
• From female subjects, collect vaginal mucosal secretion samples for immunologic assays 
as described in the Schedule of Events ( Appendix A ) 
 
DMID Protocol 19- [ADDRESS_521330]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      57 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  6.3.9 Early Termination Visit  
The following activities will be performed at the early termination visit for subjects who 
withdraw, or are withdrawn or terminated from this trial: 
• Obtain interim medical history  by [CONTACT_413649].  
• Obtain interim sexual history to identify any new sexual partners since the last study visit 
• Record all concomitant medications on the appropriate eCRF . 
• Assess all AE/SAEs and record them on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, and pulse , if needed . 
• Perform a targeted physical examination, if indicated based on review of complete 
medical history.  
• Examine vaccination site for local reactions if visit occurs ≤[ADDRESS_521331] injection. 
• Assess for reactogenicity phenomena through subject interview and review memory aid if 
visit occurs ≤[ADDRESS_521332] injection. 
• Perform a urine pregnancy test on all female subjects of childbearing potential (if 
indic ated)  
• If subject allows, obtain blood samples for immunologic assays appropriate to that visit if visit occurs within window of a regular study visit as described in the Schedule of Events 
(Appendix A ). 
• If subject allows, c ollect rectal and oropharyngeal mucosal secretion samples for 
immunologic assays appropriate to that visit if visit occurs within window of a regular study visit as described in the Schedule of Events ( Appendix A ). 
• If subject allows, f rom female subjects, collect vaginal mucosal secretion samples for 
immunologic assays appropriate to that visit if visit occurs within window of a regular study visit as described in the Schedule of Events ( Appendix A ). 
6.4 Unscheduled Study Visits  
Unscheduled visits may occur at any time during this trial. Labs may be drawn at PI [INVESTIGATOR_9106]. Any of the following activities may be performed: 
DMID Protocol 19- [ADDRESS_521333]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      58 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Obtain interim medical history  by [CONTACT_413649].  
• Record all concomitant medications on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse , if indicated . 
• Perform a targeted physical examination, if indicated based on review of complete 
medical history.  
• Examine vaccination site for local reactions if visit occurs ≤7 days after study vaccination  
• Assess for reactogenicity ph enomena through subject interview if visit occurs ≤[ADDRESS_521334] injection.  
• Obtain blood for safety if needed. 
• Perform a urine pregnancy test on all female subjects of childbearing potential (if indicated).  
• Assess all AE/SAEs and record them on the appropriate eCRF . 
6.[ADDRESS_521335] be sent to the local IRB/IEC per its guidelines  and will be reported to 
the sponsor . The site PI  [INVESTIGATOR_413612]/IEC requirements.  
DMID Protocol 19- [ADDRESS_521336]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      59 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  7 DESCRIPTION OF CLINICAL AND LABORATORY 
EV ALUATIONS 
7.1 Clinical Evaluations  
• Complete medical history will be obtained by [CONTACT_413650]. Subjects will be queried regarding a history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic system, nervous system, blood, lymph nodes, endocrine system, musculoskeletal system, skin, and genital/reproductive tract. A history of any allergies, cancer, immunodeficiency, psychiatric illness, substance abuse, and autoimmune disease will be solicited. At subsequent follow -up visits, an interim medical 
history will be obtained by [CONTACT_413651].  
• Concomitant medications will be collected as described in Section  7.1.2. 
• At the first screening visit (Visit 00A), a physical examination will be performed by a 
study clinician licensed to make medical diagnoses and listed on Form FDA [ADDRESS_521337]’s interim 
medical history. 
• Vital signs (oral temperature, pulse, and blood pressure) will be collected at each study 
visit if indicated. Vital signs assessed on the screening visits (V00A and V00B) will be considered as baseline. Subjects must not eat or drink anything hot or cold, or smoke within [ADDRESS_521338] for 10 minutes in a quiet room, and then blood pressure and/or hea rt rate may be re- measured. 
The repeated measurement may be used to determine eligibility per the judgement of the investigator. 
• Height and weight will be collected on the screening visit to determine BMI. 
• Pre-administration reactogenicity assessments will be performed before each vaccination. 
A subject with mild (Grade 1) pre- administration reactogenicity which is transient, 
resolving, or clinically insignificant may be vaccinated at the investigator’s discretion.  
DMID Protocol 19- [ADDRESS_521339]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      60 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Subjects will be observed in the clinic for ≥ [ADDRESS_521340]- administration reactogenicity assessments will be 
performed, and any AE/SAEs will be assessed and recorded on the appropriate eCRF  
before discharge from the clinic.  
• All subjects will complete a n electronic memory aid (with paper back up) on the day of 
each vaccination through seven days following each vaccination. Subject memory aids 
will be reviewed with the subjects for AEs (solicited injection site and systemic reactions, 
and unsolicited AEs). In addition, after each vaccination, whenever the subject is seen in the clinic, solicited and unsolicited reactogenicity and AEs will be reviewed.  
• Reactogenicity assessments will include an assessment of solicited AEs occurring from the time of each vaccination through seven days following each vaccination, which include injection site reactions (pruritus, erythema, ecchymosis, induration/swelling, pain, and tenderness) and systemic reactions (fever, chills/shivering/sweating, fatigue, malaise, myalgia and arthralgia (exclusive of the injection site), headache, and nausea).  
 
7.1.1 Research Procedures   
Oropharyngeal mucosal secretion sampling 
Trained, delegated study staff will be performing all oropharyngeal secretion (saliva) sampling 
procedures. Saliva will be collected and stored in the appropriate container. Instructions for 
saliva collection , handling, and storage are included in the MOP. 
Vaginal mucosal secretion sampling  
A trained, delegated clinician will be performing all vaginal mucosal sampling procedures with the assistance of a study coordinator utilizing a lubricated speculum and light source. Vaginal 
mucosal secretion samples wil l be collected and stored in the appropriate container. Instructions 
for vaginal secretion sample collection , handling, and storage are included in the MOP. 
Rectal mucosal secretion sampling and biopsy 
A trained, delegated clinician will be performing all rectal mucosal sampling procedures with the assistance of the study coordinator. 
All subjects will have rectal mucosal secretions sampled utilizing a disposable anoscope and a 
light source. A lubricated anoscope will be inserted into the anus and 2-[ADDRESS_521341]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      61 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  For subjects in the rectal mucosal biopsy cohort, a rigid sigmoidoscope, light source, and jumbo 
biopsy forceps will be utilized. Following rectal mucosal secretion sampling, without the administration of any previous enemas or other preparation, a rigid sigmoidoscope will be inserted and 8-12 adequate ~1.0 millimeter (mm) thick biopsy specimens will be taken from normal- appearing rectal mucosa approximately 10 cm ab ove the external anal aperture using 
flexible sigmoidoscopic forceps mounted on a semi-flexible rod.  All biopsy specimens will be 
coded with a unique numeric identifier such that the laboratories that receive the specimens will 
be unable to link them back to the study participants. The biopsy specimens will be placed in phosphate-buffered saline ( PBS) and transported to a lab where the specimens will be processed 
for flow cytometry. 
Twenty -four to forty -eight hours after the procedure, study personnel will call the participants 
who donated rectal biopsy samples and inquire about symptoms, complications, or adverse 
events related to study procedures. Participants who report symptoms suggestive of any significant complications will receive advice on seeking c are and will be given referrals to 
appropriate healthcare professionals as needed. This follow-up may be completed over the phone or through electronic communication.   
 7.1.2 Assessment of Concomitant Medications/Treatments  other than Study Product  
Administration of any medications, therapi[INVESTIGATOR_014], or vaccines will be documented on the appropriate 
eCRF. Concomitant medications will include all current medications and non-study vaccinations taken within [ADDRESS_521342] exclusion criteria (see Section 5.1.2). In addition, the site PI [INVESTIGATOR_168702]-investigator may identify other medications that should not be used due to a risk to subject safety or assessment of reactogenicity and immunogenicity. Use of medications as prophylaxis before study vaccination is prohibited. 
DMID Protocol 19- [ADDRESS_521343]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      62 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  To the sponsor’s knowledge, there are no known drug-vaccine interactions with the study 
vaccines and subjects are n ot being asked to discontinue current medications not listed in the 
exclusion criteria. In the event medical conditions dictate use of medications, subjects are encouraged to obtain adequate care, comply with the course of therapy as prescribed by [CONTACT_9682], and inform the Investigator as soon as practicable. Details of all medications taken during this trial (date, brand or generic name) will be recorded.  
7.[ADDRESS_521344]’s clinical screening lab evaluations (Visit 00A)  must be confirmed to meet the subject inclusion criteria 
(see Section 5.1). All s ubjects will be screened for GC and CT infection at all relevant mucosal 
sites with NAAT . Female subjects will also be screened for Trichomonas vaginalis  vaginal 
infection by [CONTACT_214347]. NAAT will be performed as follows: 
• Rectal and pharyngeal swabs, and urine specimens will be obtained from male subjects 
• Rectal and pharyngeal swabs, and self -collected vaginal swabs will be obtained from 
female subjects  
Subjects will be screened for RPR and HIV -1/[ADDRESS_521345] to be eligible to participate.  
Urine pregnancy tests will be performed by [CONTACT_413652] (Visit 00A) and within 24 hours before initial vaccination (Day 1 (Visit 01)) on all female subjects of childbearing potential. Results must be negative and known before randomization on Day 1 (Visit 01) and before receipt of vaccination. 
In the subset of participants who will undergo rectal mucosal biopsy, additional laboratory tests 
at the screening visit (Visit 00A) will include complete blood count (WBC, hemoglobin, PLT), PT and aPTT.  
 
DMID Protocol 19- [ADDRESS_521346]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      63 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Follow- Up 
Urine pregnancy tests will be performed by [CONTACT_413653] 24 hours before second 
vaccination (Day 29 (Visit 04)) on all female subjects of childbearing potential. Results must be negative and known before receipt of vaccination. 
Subjects will be re -screened for GC and CT infection at all relevant mucosal sites with NAAT 
prior to the second vaccination at  Day 29 (Visit 0 4) and at the final study visit (Day 181 (Visit 
08)) as follows:  
• Rectal and pharyngeal swabs, and urine specimens will be obtained from male subjects 
• Rectal and pharyngeal swabs, and self-collected vaginal swabs will be obtained from 
female subjects 
Subjects will also be re -screened for RPR at Day 29 (Visit 0 4) and Day 181 (Visit 08).  If a 
positive result on any of these screening tests occurs, the subject will be referred for appropriate 
follow-up and results reported as required by [CONTACT_54443] l aw. 
 
7.2.2 Research  Assays 
 
[IP_ADDRESS] Antibody assays 
Antibody assays will be performed at the study site (Stephens laboratory) and will include: 
• Measurement of IgG concentrations against GC  antigens at mucosal sites (rectum, 
vagina, oropharynx) and in serum as described in the Schedule of Events ( Appendix A ) 
by [CONTACT_28745]-linked immunosorbent assay ( ELISA ) 
• Measurement of IgA concentrations against GC  antigens at mucosal sites (rectum, 
vagina, oropharynx) and in serum as described in the Schedule of Events ( Appendix A ) 
by [CONTACT_6428]  
• Measurement of serum bactericidal antibody titers as described in the Schedule of Events 
(Appendix A ) 
• Measurement of IgG concentrations against N. meningitidis  antigens in serum as 
described in the Schedule of Events ( Appendix A ) by [CONTACT_413654] 19- [ADDRESS_521347]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      64 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  [IP_ADDRESS] Cell-mediated immunity assays 
Cell-mediated immunity assays will be performed at the study site (Hope Clinic) and will 
include: 
• Frequencies and function of memory B cells (MBC) specific for antigens from GC  and N. 
meningitidis as described in the Schedule of Events ( Appendix A ) by [CONTACT_34536] 
• Frequencies and function of peripheral blood T cells specific for antigens from GC  and 
N. meningitidis as described in the Schedule of Events ( Appendix A ) by [CONTACT_34536] 
• Frequencies, p henotype, and function of peripheral blood CD4+ and CD8+ T cells 
specific for antigens from GC  and N. meningitidis as described in the Sched ule of Events 
(Appendix A ) by [CONTACT_15242] (ICS) 
• Frequencies, phenotype, and function of rectal mucosal CD4+ and CD8+ T cells specific 
for antigens from GC  as described in  the Schedule of Events ( Appendix A ) by [CONTACT_270052] 
 
[IP_ADDRESS] Bacterial adhesion assay 
Serum for bacterial adhesion assays will be collected as described in the Schedule of Events 
(Appendix A ). For samples scheduled to be collected during vaccination visits, samples will be 
collected before vaccination.  
The bacterial adhesion assay will be performed at the study site (Stephens laboratory). Instructions for specimen preparation, handling, storage, and labeling are included in the MOP.  
 
[IP_ADDRESS] Laboratory Specimen Preparation, Handling, and Storage  
Serum for antibody assays will be collected as described in the Schedule of Events ( Appendix 
A). For samples scheduled to be collected during vaccination visits, samples will be collected 
before vaccination.  
Peripheral blood mononuclear cell (P BMC ) samples for MBC and T- cell assays will be collected 
as described in the Schedule of Events ( Appendix A ). For samples scheduled to be collected 
during vaccination visits, samples will be collected before vaccination. Plasma from the PBMC 
separations will be saved as described in the MOP.  
Instructions for specimen preparation, handling, storage, and labeling are included in the MOP.  
DMID Protocol 19- [ADDRESS_521348]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      65 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  [IP_ADDRESS] Laboratory Specimen Shippi[INVESTIGATOR_413613] (IATA) requirements and according to the specifics for storage temperature and documentation as detailed in the MOP. 
DMID Protocol 19- [ADDRESS_521349]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      66 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  8 ASSESSMENT OF SAFETY  
8.1 Assessing and Recording Safety Parameters  
Safety will be assessed by [CONTACT_12218]:  
• Any AE related to 4CMenB immunization through the end of the study. 
• Any AE related to rectal mucosal sampling procedures through the end of the study. 
• Any SAEs through the end of the study. 
 
8.1.[ADDRESS_521350] medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (investigational) product. In addition, AEs specific to the rectal mucosal biopsy cohort will be collected prior to study drug administration and are defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the rectal mucosal biopsy procedure. The occurrence of an AE may come to the attention of study personnel during study visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study monitor.  
All AEs , including solicited local (injection site) and systemic (subjective and quantitative) 
reactions , will be captured on the appropriate eCRF.   Information to be collected for AEs 
includes event description, date of onset, assessment of severity, relationship to study product 
and alternate etiology  (assessed only by [CONTACT_8703] a diagnosis 
and listed on the Form FDA 1572 as an investigator), date of resolution, seriousness and outcome.  AEs occurring during the trial collection and reporting period will be documented appropriately regardless of relationship.  AEs will be followed through resolution. 
[IP_ADDRESS] Adverse Events Grading  
All AEs  (clinical symptoms)  will be graded for severity and assessed for relationship to study 
product (see definitions) . AEs  characterized as intermittent require documentation of onset and 
duration of each epi[INVESTIGATOR_1865].  The start and stop date of each reported AE will be recorded on the 
DMID Protocol 19- [ADDRESS_521351]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      67 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  appropriate eCRF.  Changes in the severity of an AE will be docume nted to allow an assessment 
of the duration of the event at each level of intensity. 
 Severity of Event:    
AEs will be assessed by [CONTACT_55296] a protocol-defined grading system (toxicity table 
included as an appendix).  For events not included in the protocol-defined grading system, the 
following guidelines will be used to quantify severity: 
• M
ild (Grade 1) :  Events that are usually transient and may require  only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the subject’s 
usual activities  of daily  living . 
• Moderate (Grade 2) :  E vents that are usually alleviated with additional specific 
therapeutic intervention .  The event interferes with usual acti vities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. 
• Severe (Grade 3) :   Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  Severe events are usually incapacitating. 
 
R
elationship to Study Product: The  assessment of the AE’s relationship  to study product will 
be done by [CONTACT_149087] [ADDRESS_521352] 
will be assessed for AEs using the terms related or not related:  
• R
elated  – There is a reasonable possibility that the study product caused the AE . 
Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the AE . 
• Not Related  – T
 here is not a reasonable possibility that the administration of the study 
product caused the event. 
 
DMID Protocol 19- [ADDRESS_521353]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      68 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  8.1.2 Reactogenicity  
Reactogenici ty events are AEs that are common and known to occur following administration of 
this type of study vaccine. The Toxicity Grading Scale ( Appendix C ) will be used to grade 
solicited local (injection site) and systemic (subjective and quantitative) reactions . 
8.1.3 Serious Adverse Events   
An AE  or suspected adverse reaction is considered a SAE if, in the view of either the site PI  [INVESTIGATOR_149057], it results in any of the following outcomes:  
• Death,  
• a life -threatening adverse event1,  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or  
• a congenital anomaly/birth defect.   
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency room  or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
1 Life-threatening adverse event. An AE  is considered “life-threatening” if, in the view of either 
the site p rincipal  investigator or sponsor, its occurrence places the patient or subject at immediate 
risk of death.  It does not include an AE  that, had it occurred in a more severe form, might have 
caused death.  
SAEs will be: 
• Assessed for severity and relationship to study product or procedure and alternate 
etiology (if not related to study product) by a licensed study physician listed on the Form FDA 1572 or by [CONTACT_149088]  [INVESTIGATOR_54720] -Investigator. 
• Recorded on the appropriate SAE eCRF. 
DMID Protocol 19- [ADDRESS_521354]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      69 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  • Followed through resolution by a licensed study physician (for investigational new drug 
application ( IND) studies, a physician listed on the Form FDA 1572 as the site PI  [INVESTIGATOR_54720]-
Investigator). 
• Reviewed and evaluated by [CONTACT_122830] , an Independent Safety Monitor (I SM) (as deemed 
necessary), or Safety Monitoring Committee ( SMC ) (periodic review unless related), and 
the IRB/IEC . 
8.2 Specification of Safety Parameters  
Safety will be assessed by [CONTACT_12218]:  
• Any AE related to 4CMenB immunization through the end of the study. 
• Any AE related to rectal mucosal sampling procedures through the end of the study. 
• Any SAEs through the end of the study. 
 
8.2.[ADDRESS_521355]. The Toxicity Grading Scale ( Appendix C ) will be used to grade solicited local (injection 
site) and systemic (subjective and quantitative) reactions . All subjects will complete a subject 
memory aid on the day of each vaccination through 7 days after each vaccination  (i.e. Day 8 and 
Day 3 6 visits) . Subject memory aids will be reviewed with the subjects for AEs  (solicited 
injection site and systemic reactions, and unsolicited AEs). In addition, after each vaccination, 
whenever the subject is seen in the clinic or a phone call occurs (i.e., at all opportunities), solicited and unsolicited reactogenicity and AEs will be reviewed. Reactogenicity assessments will include an assessment of solicited AEs occurring from the time  of each vaccination through 
seven days following each vaccination, which include injection site reactions (pruritus, erythema, ecchymosis, induration/swelling, pain, and tenderness) and systemic reactions (fever, chills/shivering/sweating, fatigue, malaise, myalgia and arthralgia  (exclusive of the injection 
site), headache, and nausea).  
Solicited injection site and systemic reactogenicity events will be documented and reported from Day [ADDRESS_521356]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521357]. Unsolicited AEs will be collected and assessed through the end of the protocol -defined follow up period. Unsolicited AEs are followed through resolution or 
stabilization even if this extends beyond the reporting period. 
8.2.3 Medically -Attended Adverse Events (MAAEs)  
For each AE experienced, the subject will be asked if he/she had rec eived medical attention, 
defined as hospi[INVESTIGATOR_059], an ER visit, or an otherwise unscheduled visit to or from medical 
personnel for any reason. AEs characterized by [CONTACT_413655].  
8.3 Reporting Procedures  
Any medical condition that is present at the time that the subjec t is screened will be considered 
as baseline and not reported as an AE.  However, if the severity or frequency of any pre-existing 
medical condition worsens, it should be recorded as an AE. 
If an event meets both the criteria of a study endpoint and an AE , the event will be reported 
either as a study endpoint or as an AE  (not both). 
For the rectal bi opsy cohort, SAEs  will be documented and reported from the time of the 
baseline rectal mucosal  biopsy through approximately [ADDRESS_521358] be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group 
Clinical Research Operations and Ma nagement Support (CROMS)  
[ADDRESS_521359]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      71 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line:  
SAE FAX Number:  
SAE Email Address:  
In addition to the SAE form, select SAE data fields must also be entered into the data 
coordinating center ( DCC ) system . Please see the protocol -specific MOP for details regarding 
this procedure.  
Other supporting documentation of the event may be requested by [CONTACT_154385].  
The site will send a copy of the SAE report(s) to the DMID Pharmacovigilance Group. The 
DMID Medical Monitor and DMID Clinical Project Manager will be notified of the SAE by [CONTACT_413656].  The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct. 
At any time after completion of the study, if the site  principal investigator [INVESTIGATOR_29353]-
investigator becomes aware of an SAE that is suspected to be related to study product, the site PI  
[INVESTIGATOR_29353]-investigator will report the event to the DMID Pharmacovigilance Group.  8.3.2 Regulatory Reporting f or Studies Conducted Under DMID -Sponsored IND  
Following notification from the site PI  [INVESTIGATOR_29353]-investigator, DMID, as the IND 
sponsor, will report any suspected unexpected serious adverse event  (S[LOCATION_003]R) as an IND safety 
report to the FDA and will notify all participating site PIs (i.e., all PIs to whom the sponsor is 
providing drug under its IND(s) or under any PI’s  IND(s)) of potential serious risks from clinical 
studies or any other source, as soon as possible. DMID will report to the FDA any unexpected 
fatal or life -threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the sponsor’s initial receipt of the information.  If the event is not fatal or life -
threatening the IND safety report will be submitted within  [ADDRESS_521360]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521361] Values or Abnormal Clinical Findings  
The site PI [INVESTIGATOR_29353]-investigator is responsible for recording all AE/SAEs that are 
observed or reported during this trial, regardless of the relationship to the vaccine. AE/SAEs or abnormal clinical findings will be collected, assessed,  documented, reported, and followed 
appropriately. 
All subjects will be screened for GC and CT infection at all relevant mucosal sites with  NAAT at 
screening (Visit 00A) and prior to rectal mucosal sampling procedures at Day 29 (Visit 0 4) and 
at the final study visit (Day 181 (Visit 08)). Female subjects will also be screened for 
Trichomonas vaginalis  infection with NAAT at screening (Visit 00A). Subjects will also be 
screened for RPR at screening (Visit 00A) , Day 29  (Visit 0 4) and Day 181 (Visit 08) , as well as 
HIV-1/2 antibody (Visit 00A and 08). If a positive result on any of these screening tests occurs, 
the subject will be referred for appropriate follow-up and results reported as required by [CONTACT_76522]. 
DMID Protocol 19- [ADDRESS_521362]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      73 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Safety labs will only be required at screening in the rectal biopsy cohort. Safety labs may be 
repeated during the study at the investigator’s discretion as part of the assessment of abnormal clinical findings.  
 
8.6 Halting Rules  
8.6.1 Study Halting Criteria  
The study will be halted for SMC review/recommendations if any of the following are reported:   
• Any subject experiences an SAE after administration of study product that is considered 
related to study product. 
• Any subject experiences an SAE after a study procedure that is considered related to the study procedur e. 
• An overall pattern of symptomatic, clinical, or laboratory events that the DMID Medical Monitor ( MM) or SMC consider associated with the study product and that may appear 
minor in terms of individual events, but that may collectively represent a serious potential 
concern for safety . 
If any of the halting rules are met, the study will not continue without a review of the safety data by [CONTACT_413657].  
SMC retains the authority to suspend additional enrollment and administration of the study product during the entire study, as applicable. 
 
8.6.[ADDRESS_521363] will be discontinued from second vaccination if :  
• Subject develops a new medical condition or medication change for which continued 
participation, in the opi[INVESTIGATOR_871], would pose a risk to the subject 
• Subject is no longer willing and/or able to adhere to study restrictions outlined in the Inclusion and Exclusion Criteria 
• Subject has a fever (defined as an oral temperature ≥38.0 °C) or an acute illness at the time of boost vaccination administration. The next study vaccination can be deferred until 
DMID Protocol 19- [ADDRESS_521364]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521365] is given within the protocol-defined study window.  
• Subject has received COVID -19 vaccine <14 days prior to scheduled dose #2. The next 
study vaccination can be deferred until at least [ADDRESS_521366] is given within the 
protocol-defined study window. 
• Permission to administer vaccination outside the protocol-defined study window must be 
obtained from DMID Medical Officer. 
Note: In case the boost vaccination is postponed, the timing of t he safety/immunogenicity visits 
post-boost will be planned relative to actual vaccination day. 
8.7 Safety Oversight  
8.7.1 Independent Safety Monitor (ISM)  
For this clinical trial an ISM is not required .  H owever, upon DMID Medical Monitor 
request,  the PI [INVESTIGATOR_69059] a physician with relevant expertise, to act as a Secondary Medical 
Assessor (SMA) . The SMA will examine a subject and/or medical records and provide a medical 
assessment (or second medical opi[INVESTIGATOR_1649]) to the DMID of the safety event in question. The PI [INVESTIGATOR_413614], a summary of the event and include the PI [INVESTIGATOR_413615].   
Note: In the case that DMID has requested this type of evaluation multiple times, DMID may 
r
equest the site(s) identify an ISM to assist DMID with safety oversight.  
 
8.7.2 Safety Monitoring Committee (SMC)  
This clinical study will utilize an SMC, which is an independent group of experts that advises the 
DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is external 
to the DMID and comprises at l east [ADDRESS_521367]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521368] ad hoc reviews as appropriate 
when a halting rule is met or for immediate concerns regarding observations during this study. 
The SM C will convene for the following meetings: Organizational meeting, scheduled data 
review meetings, ad hoc meetings for a specific safety concern or issue, final meeting. 
DMID Protocol 19- [ADDRESS_521369]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521370] /Independent Ethics Committee  
Each  site PI  [INVESTIGATOR_149059]/her research site(s), 
and send supporting documentation to the DMID before initiating recruitment of subjects.  The 
investigator will submit applicable information to the IRB/IEC on  which it relies for the review, 
to conduct the review in accordance with 45 CFR 46, ICH E6 GCP, and as applicable, 21 CFR 
56 (Institutional Review Boards) and 21 CFR 50 (Protection of Human Subjects) , other federal, 
state, and local regulations. The  I RB/I EC must be registered with OHRP as applicable to the 
research.  DMID  must receive the documentation that verifies IRB/IEC -approval for this 
protocol, associated informed consent documents, and upon request any recruitment material and 
handouts or surveys intended for the subjects, prior to the recruitment and enrollment of subjects.     
Any amendments to the protocol or consent materials will be approved by [CONTACT_1201]/IEC before 
they are implemented.  IRB/IEC review and approval will occur at least annually throughout the 
enrollment and follow-up of subjects, and may cease if annual review is no longer required by 
[CONTACT_149091]/IEC .  The investigator will notify the IRB/IEC of deviations 
from the protocol and reportable SAEs, as applicable to the IRB/IEC policy. 
The institution engaged in this research will hold a current FWA issued by [CONTACT_413658].  
9.2 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation.  Before any study procedures are performed, informed consent will be obtained and documented.  Subjects will receive a concise and focused presentation of key information about the clini cal trial, verbally and with a 
written consent form. The explanation will be organized, and presented in lay terminology and language that facilitates understanding why one might or might not want to participate. 
An investigator or designee will describe the protocol to potential subjects face- to-face. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
risks and discomforts, any expected benefits to the subject, and alternative treatment will be present ed first to the subject.   
DMID Protocol 19- [ADDRESS_521371]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      77 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Subjects will also receive an explanation that the trial involves research, and a detailed summary 
of the proposed study procedures and study interventions/products.  This will include aspects of the trial that are experimental, the probability for random assignment to treatment groups, any expected benefits, all possible risks (including a statement that the particular treatment or procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may beco me pregnant, that are currently unforeseeable), and the expected duration of the subject’s 
participation in the trial.  
Subjects will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their w illingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are available if injury occurs, and, if so, what they consist of, or where further information may be obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payments, if any, to the subject for participating in the trial. They will be informed of whom to contact (e.g., the investigator) for answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may be terminated. The subjects  will be informed that 
participation is voluntary and that they are free to withdraw from the study for any reason at any time without penalty or loss of benefits to which the subject is otherwise entitled.   
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. Subjects will be informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct access to the subject’s original medical records for verification of clinical trial procedures and/or data without violating the confidentiality of the subject, to the extent permitted by [CONTACT_4913], and that, by [CONTACT_2960] a written informed consent form, the subject is authorizing such access.  
Subjects will be informed that records identifying the subject will be kept confidential, and, to 
the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available and,  if the results of the trial are published, the subject’s identity will remain 
confidential. Subjects will be informed whether private information collected from this research and/or specimens will be used for additional research, even if identifiers are removed.   
Subjects will be allowed sufficient time to consider participation in this research trial, and have the opportunity to discuss this trial with their family, friends or legally authorized representative, or think about it prior to agreeing to part icipate.  
DMID Protocol 19- [ADDRESS_521372]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521373](s) for their records.  The subject(s) 
may withdraw consent at any time throughout the course of the trial.  The rights and welfare of 
the subject(s) will be protected by [CONTACT_413659].  
Study personnel may employ recruitment efforts prior to obtaining study consent if a patient-s
pecific screening consent is on record or if the IRB has agreed that chart review is allowed 
without a fully executed screening consent.  In cases where there is not a patient- specific 
screening consent on record, site Clinical staff  may pre- screen via chart review and refer 
potential subjects to the Research staff.  Research staff would obtain written cons ent per the 
standard informed consent process before conducting protocol- specific screening activities.  
New information will be communicated by [CONTACT_7880]  t o subjects who consent to participate in 
this trial in accordance with IRB requirements.  The informed consent document will be updated and subjects will be re-consented per IRB requirements, if necessary.  Subjects will be given a copy of all ICFs  that they sign. 
Human Genetic Testing  
No human genetic testing will be performed in this study. 
9.3 Consent fo r Future Use of Stored Specimens and Data  
Residual samples/specimens and data are those that are left over after protocol -specified testing 
and this study has been completed. Subjects will be asked for permission to keep any data and any remaining (residual) specimens (serum and PBMCs) derived from venous blood samples, swabs and other mucosal samples  for possible use in future research studies, such as examining 
additional immunological assessments or testing for antibodies against other viruses or bacteria. These residual specimens will be stored coded indefinitely at a DMID -contracted storage facility .  
Data or specimens may be shared with investigators a t the participating site and with other 
investigators at U.S. or international institutions. The recipi[INVESTIGATOR_413616] a NIH certificate of confidentiality. The information provided to a recipi[INVESTIGATOR_413617]. Use of the specimens will require a new protocol and review  and approval of that protocol and the specimens for use by [CONTACT_113834].    
DMID Protocol 19- [ADDRESS_521374]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      79 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  There are no benefits to subjects in the collection, storage and subsequent future use of their 
data/samples/specimens. These data/ samples/specimens will not be sold or used directly for 
production of any commercial product. The data/ sample/specimen will be encoded (labeled) only 
with a barcode and a unique tracking number that connects to a code key at the study site. Restricted access to the code key is maintained by [CONTACT_458] [INVESTIGATOR_413618]. Reports from future research studies performed using subjects’ 
data/ samples/specimens will NOT be kept in the ir health records.  
Subjects may be given the option to decide if they want their residual  
 specimens with their data 
to be used for future research or have these specimens destroyed at the end of this trial. The 
subject’s decision can be changed at any time by [CONTACT_154387]. 
However, if the subject originally consents to the future use of residual  specimens with their 
data and subsequently changes his/her decision, any data already collected from a previously 
collected specimen may still be used for future research.  
9.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will include all healthy adults who meet the inclusion/exclusion criteria, regardless of 
religion, sex, or ethnic background. Only subjects, aged [ADDRESS_521375] by [CONTACT_3486], their staff, and the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, subject’s clinical information, and all other information generated during participation in the 
study. No information concerning the study or the data generated from the study will be released 
to any unauthorized third party without prior written approval of the DMID and the subject. Subject confidentiality will be maintained when study results are published or discussed in conferences.  The study monitor or other authorized representatives of the sponsor or governmental regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study. The clinical study site will permit access to such records.  
DMID Protocol 19- [ADDRESS_521376]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521377]’s consent, information that would identify the subject as a participant in the research project regarding matters that must be legally reported including: child and elder abuse, sexual abuse, or wanting to harm themselves or others.   
The release of individual private information or specimens for other research will only occur if 
c
onsent was obtai ned from the individual to whom the information, document, or biospecimen 
pertains, or  for the purposes of other research that is in compliance with applicable Federal 
regulations governing the protection of human subjects in research.  
 
9.[ADDRESS_521378]’s insurance or third party.  Subjects may be compensated for their participation in this trial.  
DMID Protocol 19- [ADDRESS_521379]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      81 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Compensation will be in accordance with the local IRB’s policies and procedures, and subject to 
IRB approval. 
If it is determined by [CONTACT_7880]  [INVESTIGATOR_122767] a subject as a direct result of the tests 
or treatments that are done for this trial, then referrals to appropriate health care facilities will be 
provided to the subject.  Study personnel will try to reduce, control, and treat any complications from this trial.  Immediate medical treatment may be provided by [CONTACT_16529].  No 
financial compensation will be provided to the subject by [CONTACT_122845], NIH to the subj ect by [CONTACT_413660] y injury suffered due to participation in this trial. 
 
DMID Protocol 19- [ADDRESS_521380]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521381] any hypotheses, p-values may be reported that compare the immunogenicity and/or safety data between treatment groups. The null hypotheses for these tests will be that there is no difference between treatment group s and the alternative hypotheses will be two -sided.  
10.2 Sample Size Considerations  
A total of  approximately 50 (maximum of 60), subjects will be enrolled and randomized to one 
of two study arms based on a 4:1 allocation ratio to the 4CMenB arm and p lacebo arm , 
respectively .. The 4:[ADDRESS_521382] any hypotheses associated with the immunogenicity data.  Using the ELISA GMT estimates  reported in Table 2  of Semchenko et al. ,
13 estimated 
GMT  95% confidence intervals were calculated for the 4CMenB group using the post-
vaccination estimates and for the placebo group using the pre- vaccination estimates . Table 2  
provides the estimated GMTs and GMT ratio s between groups. To account for a small 
percentage of the approximate 50 randomized subjects not being eligible for the primary analysis (e.g., due to not having immunogenicity data available), a range of sample sizes from [ADDRESS_521383]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      83 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Table 2: 95% Confidence Intervals for GMTs and GMT Ratios across a range of 
Sample Sizes and Antigens  
N 
(Vaccine / 
Placebo)  Antigena Treatment 
Group  GMT 
Estimate  GMT 95% CI  GMT 
Ratio  GMT Ratio 
95% CI  
30 / 6 Ng OMV  Vaccine  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  1.23 0.77, 1.97 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
Ng whole 
cell Vaccine  [ZIP_CODE]  [ZIP_CODE], 100721  1.62 0.86, 3.05 Placebo  [ZIP_CODE]  [ZIP_CODE], 121713  
Nm whole 
cell Vaccine  388023  262806, 572900  4.00 1.53, 10.47 Placebo  [ZIP_CODE]  [ZIP_CODE], 321311  
Ng rNHBA  Vaccine  1176267  876783, 1578046  34.3 16.98, 69.26 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
35 / 8 Ng OMV  Vaccine  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  1.23 0.81, 1.87 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
Ng whole 
cell Vaccine  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  1.62 0.93, 2.83 Placebo  [ZIP_CODE]  [ZIP_CODE], 100944  
Nm whole 
cell Vaccine  388023  271134, 555305  4.00 1.73, 9.26 Placebo  [ZIP_CODE]  [ZIP_CODE], 251856  
Ng rNHBA  Vaccine  1176267  897654, 1541356  34.3 18.63, 63.14 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
40 / 10  Ng OMV  Vaccine  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  1.23 0.85, 1.79 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
Ng whole 
cell Vaccine  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  1.62 0.98, 2.68 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
Nm whole 
cell Vaccine  388023  277922, 541742  4.00 1.88, 8.51 Placebo  [ZIP_CODE]  [ZIP_CODE], 219456  
Ng rNHBA  Vaccine  1176267  914549, 1512881  34.3 19.85, 59.27 Placebo  [ZIP_CODE]  [ZIP_CODE], [ZIP_CODE]  
a: From Semchenko (2018) , Table [ADDRESS_521384]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      84 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  10.3 Treatment Assignment Procedures  
10.3.1 Randomization Procedures  
Within each biopsy cohort (Rectal Mucosal Biopsy Cohort and No Rectal Mucosal Biopsy 
Cohort), subjects will be randomized 4:1 to 4CMenB or placebo. Randomization will be 
stratified by [CONTACT_4321]. Approximately twenty (20) subjects, approximately [ADDRESS_521385] of randomized treatment assignments will be included in the enrollment module of 
Emmes’ Internet Data Entry System (IDES).  Advantage eClinical® will assign each enrolled participant to a treatment arm after demographic and eligibility data have been entered into the 
system.  A designated individual at each participating site will be provided with a coded list for emergency unblinding purposes, which will be kept in a secure pla ce. 
Instructions for use of the enrollment module are included in the Advantage eClinical User’s Guide.  Manual back-up procedures and instructions are provided for use in the event that a participating site temporarily loses access to the Internet or the online enrollment system is unavailable.  
10.3.[ADDRESS_521386] administration, data entry personnel at the sites, and laboratory personnel performing study assays will be blinded to treatment assignment. 
Syringes will be labeled with an overlay/blinding tape containing the subject ID, and the treatment number from the treatment key, and expi[INVESTIGATOR_413619], and provided to 
the unblinded vaccine administrator. The unblinded vaccine administrator will be credentialed to 
administer vaccines but will not be involved in study- related assessments, subject contact, or 
data collection following vaccination  (data entry related to the vaccination is acceptable) . 
The randomization scheme will be generated by [CONTACT_63662]  
(SDCC ) and provided to unblinded study personnel (i.e., research pharmacists performing study 
product preparations and unblinded study product administrators) at the participating sites. The 
unblinded study product administrator is a study personnel member credentialed to administer study product and may also participate in dose preparation but will not be involved in study-related assessments or have participant contact [CONTACT_413661].  
DMID Protocol 19- [ADDRESS_521387]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521388] 20 
subjects who complete V isit 6, which includes data addressing the primary and secondary 
objectives, as well as several exploratory objectives . The interim report will be prepared by [CONTACT_413662] V isit 6  are 
received.  Results will be shared only with relevant study personnel (i.e. PI, laboratory 
investigator(s), and DM ID) and only in aggregate by [CONTACT_2939]. Study personnel will remain 
blinded to individual subject treatment assignments. 
The interim immunogenicity analyses will include summaries of descriptive and aggregate 
antibody data against antigens from Neisseria gonorrhoeae and Neisseria meningitidis stratified 
by [CONTACT_488], specimen type (serum and mucosal sites) , pre- versus post- treatment timepoints, and 
treatment arm (4C MenB or placebo).  No hypothesis tests or modeling will be included in the 
interim immunogenicity analysis. This interim analysis of the data is not intended to impact the 
conduct of this trial. No statistical adjustments are planned. 
10.5 Final Analysis Plan  
A separate Statistical Analysis Plan (SAP) will be written that will contain the details of all planned analyses.  This section outlines the major components of the analyses. 
DMID Protocol 19- [ADDRESS_521389]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      86 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  10.5.1 Analysis Populations 
[IP_ADDRESS] Immunogenicity Population 
For the primary outcome analysis, the Immunogenicity Population at a specified follow-up visit 
will include all eligible subjects who have received all  doses of study product prior to that visit 
and have immunogenicity data available for that visit.  Subjects will be classified according to 
the study product received.  To account for subjects having data available only for a subset of 
assays, assay -specific populations will be defined.   
Per-protocol populations may also be defined that further restrict the immunogenicity analysis 
populations to exclude subjects with major protocol deviations or events that may impact study 
product effectiveness or the ascertainment or interpretation  of assay results .  These will be 
described in the SAP . For supplementary and exploratory analyses, additional analysis 
populations may be defined; details will be provided in the SAP .  
[IP_ADDRESS] Safety Population 
The Safety Population will include all subjects who received at least one dose of study product.  Subjects will be classified according to the treatment received.  
10.5.[ADDRESS_521390] deviation, median, minimum, and maximum. For categorical variables, descriptive statistics will include counts and percentages per category. 
10.5.3 Immunogenicity Analysis Plan 
For the analyses of the primary and secondary immunogenicity outcomes, the GMT and 
geometric mean fold rise (GMFR) for ELISA titers will be calculated for Days 1, 29, 43, 57, and 181 in each study arm.  Point estimates and their 95% confidence intervals will be reported for each ti me point.  The distribution of titers will also be graphically summarized using reverse 
cumulative frequency distributions.  Anatomical sites will be summarized separately.   
Summaries of the ratio of serum to mucosal IgG concentration will be generated at each time 
point.  Geometric means and confidence intervals will be reported and scatter plots of serum vs. 
mucosal IgG concentrations will be generated.   Summaries of pairwise concentration ratios, 
comparing anatomical sites , will also be generated  at each time point .  Summaries will include 
geometric means and confidence intervals as well as graphical summaries.   
DMID Protocol 19- [ADDRESS_521391]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521392] of pote ntial outliers.  
Additional supplementary and/or sensitivity  analys es of the primary and secondary outcomes as 
well as analysis of the exploratory immunogenicity outcomes will be described in the separate SAP.  
10.5.[ADDRESS_521393] administration through the final study visit.  
AEs and SAEs will be coded by [CONTACT_413663] ( MedDRA® ) for 
preferred term and system organ class. The rate and exact 95% CIs of AEs and SAEs in aggregate, as well as by [CONTACT_270662], will be computed. The number of SAEs will be reported by a detailed listing showing the type, MedDRA coding, relevant dates (treatment dosing date(s) and SAE onset and resolution dates), severity, relatedness, and outcome for each event.  
Solicited local injection site and systemic reactogenicity will be summarized by [CONTACT_413664] (for each injection) and as the maximum severity over the entire assessment period (across injections). Additionally, solicited AEs will be analyzed by [CONTACT_413665]-up period, dichotomizing into a binary variable (none vs. any severity) 
and using exact confidence intervals to summaries the proportion/percentage of subjects reporting each symptom any infection site symptom, and any systemic symptom.  Solicited AEs will be summarized separately for each infection, and over both injections by [CONTACT_30157]. 
Vital sign and physical exam findings will also be summarized  and/or providing in subject- level 
listings . 
Missing safety data will not be imputed and no search for outliers will be performed.  
DMID Protocol 19- [ADDRESS_521394]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      88 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  11 ELECTRONIC CASE REPORT FORMS AND ACCESS 
TO SOURCE DATA   
The participating VTEU site will maintain appropriate medical and research records in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects. The  site will permit authorized representatives of 
DMID, its designees, and appropriate regulatory agencies to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study sa fety and progress. These representatives will be permitted access to 
all source data and source documents (paper and electronic), which include, but are not limited 
to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial. Source data are all information, 
original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. 
The study uses direct data entry for the participating clinic site. All eCRFs serve as the source 
documents.  
Subject memory aids will not be source documents. Subjects will be trained to use a database to 
complete a web based “e -Memory aid” and are expected to enter information in the e-Memory 
aid each day. Subjects using the e-Memory aid will also be provided a paper memory aid for their use in the event they are unable to access the web -based system. The subjects will be asked 
to enter the information from the paper memory aid into the e-Memory aid once they are able to access the web -based system.  Subjects will record temperature, local and systemic symptoms 
and any new medications used following vaccination or changes to previously reported medications daily for [ADDRESS_521395]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521396]- entered data will be available for review by [CONTACT_413666] g the 
clinical interview.  
The site staff will be the data originators for the clinically reviewed data in Advantage 
eClinical® that will be used for the study endpoints. A list of all authorized site staff data originators will be included on the Study Personnel/Signature [CONTACT_122868].  
DMID Protocol 19- [ADDRESS_521397]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      90 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  12 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, the participating site  is 
responsible for conducting routine QA and quality control (QC) activities to internally monitor 
study progress and protocol compliance.  The site principal investigator [INVESTIGATOR_262600]/eCRF s and reports for the purpose of monitoring and auditing by [CONTACT_103], and inspection by [CONTACT_9177].  The site PI  [INVESTIGATOR_366454]. 
The SDCC will implement quality control procedures beginning with the data entry system and 
generate data quality control ch ecks that will be run on the database.  Any missing data or data 
anomalies will be communicated to the participating site  for clarification and resolution. 
 
DMID Protocol 19- [ADDRESS_521398]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521399] KEEPI[INVESTIGATOR_1645]  
13.1 Data Management Responsibilities  
The site PI  [INVESTIGATOR_307589], completeness, legibility, and t imeliness of the 
data reported.  
Data will be entered electronically over the Internet by [CONTACT_122860], 
developed and maintained by [CONTACT_80938]. The eCRFs serve as the source documents for data collected.  Paper case report forms derived from the eCRF are provided by [CONTACT_413667]. Details on data handling procedures, procedures for data monitoring, and instructions for use of the system and completion of the 
eCRFs are provided in the study MOP, eCRF Instructions, and Advantage eClinical User’s 
Guide. 
The sponsor and/or its designee will provide guidance to the site principal investigators and other 
study personnel on making corrections to the eCRF. 
13.2 Data Coordinating Center/Biostatistician Responsibilities  
All eCRFs  and laboratory reports must be reviewed by [CONTACT_71509], who will ensure that they are accurate and complete. AEs  must be recorded on the 
appropriate eCRF , assessed for severity and relationship, and reviewed by [CONTACT_7880]  [INVESTIGATOR_168702]-investigator. 
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site PI . During the study, the site PI  [INVESTIGATOR_149064]. 
The SDCC for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data. 
13.3 Data Capt ure Methods  
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, physical assessments, and clinical laboratory values), reactogenicity and immunogenicity data will be entered into eCRFs via a [ADDRESS_521400]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521401] of all authorized data originators, including site staff, will be included on the Study Personnel/Signature [CONTACT_122868]. 
13.4 Types of Data  
Data for this trial will include clinical, safety, and outcome measures (e.g., clinical laboratory values, reactogenicity, and immunogenicity data). 
13.[ADDRESS_521402] for th e indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for the study 
product, until 2 years after the investigation is discontinued and the FDA has been notified. 
These documents will be retained for a longer period, however, if required by [CONTACT_427]. ICFs for future use will be maintained as long as the sample/specimen exists.  
No records will be destroyed without the written consent of the sponsor. It is the responsibility of 
the sponsor to inform the site PI  [INVESTIGATOR_135830]. The 
participating VTEU sites must contact [CONTACT_295069]. 
 
DMID Protocol 19- [ADDRESS_521403]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      93 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  14 CLINICAL MONITORING  
Site monitoring is conducted to ensure that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is conducted in accordance with the protocol, protocol-specific MOP and applicable sponsor standard operating procedures (SOP) .  DMID, the sponsoring agency, or its designee will 
conduct site- monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by [CONTACT_202422].  Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, eCRFs, ICFs , medical and laboratory reports, and 
protocol and GCP compliance.  Site monitors will have access through study personnel, and all study documentation according to the DMID-approved site monitoring plan.  Study monitors will meet with the site PI  [INVESTIGATOR_413620], and will document site 
visit findings and discussions. 
DMID Protocol 19- [ADDRESS_521404]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521405] submitted for 
them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) 
an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than [ADDRESS_521406] be accessible to the public on PubMed Central no later than 12 months after publication. 
Refer to:  
• NIH Public Access Policy,  http://publicaccess.nih.gov/ 
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm 
As of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_521407] applied for certification of delayed posting. 
As part of the result posting a copy of this protocol (and its amendments) and a copy of the SAP  
will be posted on ClincialTrials.gov. For this trial the responsible par ty is DMID  which will register the trial and post results.   
The responsible part y does not plan to  request certification of delayed posting. 
Refer to:  
• Public Law 110-85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-[ADDRESS_521408]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      95 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  16 LITER ATURE REFERENCES  
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, 
Gottlieb S, Kiarie J, Temmerman M. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015;10(12):e0143304. doi: 10.1371/journal.pone.0143304. PubMed PMID: 26646541; PMCID: PMC4672879. 
2. Gonorrhea: Division of STD Prevention; 2018 [cited 2019 March 22]. Available from: 
https://www.cdc.gov/std/stats17/gonorrhea.htm. 
3. Katz AR, Komeya AY, Kirkcaldy RD, Whelen AC, Soge OO, Papp JR, Kersh EN, 
Wasserman GM, O'Connor NP, O'Brien PS, Sato DT, Maningas EV, Kunimoto GY, Tomas JE. Cluster of Neisseria gonorrhoeae Isolates With High -level Azithromycin Resistance and 
Decreased Ceftriaxone Susceptibility, Hawaii, 2016. Clin Infect Dis. 2017;65(6):918-23. doi: 10.1093/cid/cix485. PubMed PMID: 28549097. 
4. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear- Smith F, Black 
S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against 
gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390([ZIP_CODE]):1603-10. doi: 10.1016/S0140-6736(17)[ZIP_CODE]-6. PubMed PMID: 28705462. 
5. Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis- Harris H. 
Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing 
Hospi[INVESTIGATOR_413621]: A Retrospective Cohort Study. Vaccines (Basel). 2 019;7(1). doi: 10.3390/vaccines7010005. PubMed PMID: 30621260. 
6. Whelan J, Klovstad H, Haugen IL, Holle MR, Storsaeter J. Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway. Emerg Infect Dis. 2016;22(6):1137-9. doi: 10.3201/eid2206.151093. PubMed PMID: 27191543; PMCID: PMC4880101. 
7. Pérez O, Campo Jd, Cuello M, González E, Nuñez N, Cabrera O, Llanes R, Acevedo R, 
Zayas C, Balboa J, Romeu B, Baró M, Campa C, Lantero MI, Sierra G, Galindo MA, Harandi AM, Lastre M. Mucosal approaches in Neisseria vaccinology. VacciMonitor. 2009;18(2):53-5. 
8. Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas 
A, O'Hallahan J, Rosenqvist E, Black S. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the 
DMID Protocol 19- [ADDRESS_521409]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      96 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  future. Hum Vaccin Immunother. 2013;9(6):1241-53. doi: 10.4161/hv.[ZIP_CODE]. PubMed PMID: 
23857274; PMCID: PMC3901813. 
9. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epi[INVESTIGATOR_413622] 
P1.7-2,4 protein is the major target for the immune response elicited by [CONTACT_413668]-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486-91. doi: 10.1128/CVI.13.4.[PHONE_8587]. PubMed PMID: 16603616; PMCID: PMC1459632. 
10. MacNeil JR, Rubin L, Folaranmi T, Ortega- Sanchez IR, Patel M, Martin SW. Use of 
Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of 
the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-6. doi: 10.[ZIP_CODE]/mmwr.mm6441a3. PubMed PMID: 26492381. 
11. [COMPANY_004] Vaccines. Bexsero Prescribing Information. 2015. 12. Longtin J, Dion R, Simard M, Betala Belinga J-F, Longtin Y, Lefebvre B, Labbe A-C, 
Deceuninck G, De Wals P. Possible Impact of Wide-scale Vaccination Against Serogroup B Neisseria Meningitidis on Gonorrhea Incidence Rates in One Region of Quebec, Canada.  IDWeek 2017; San Diego, CA. 2017. 
13. Semchenko EA, Tan A, Borrow R, Seib KL. The serogroup B meningococcal vaccine 
Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2018. doi: 10.1093/cid/ciy1061. PubMed PMID: 30551148. 
14. Beernink PT, Ispasanie E, Lewis LA, Ram S, Moe GR, Granoff DM. A Meningococcal 
Native Outer Membrane Vesi cle Vaccine With Attenuated Endotoxin and Overexpressed Factor 
H Binding Protein Elicits Gonococcal Bactericidal Antibodies. J Infect Dis. 2019;219(7):1130-7. doi: 10.1093/infdis/jiy609. PubMed PMID: 30346576. 
15. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease C. Use of 
Serogroup B Meningococcal Vaccines in Persons Aged >/=10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608-12. Epub 2015/06/13. PubMed PMID: 26068564; PMCID: PMC4584923. 
16. Duffy J, Johnsen P, Ferris M, Miller M, Leighton K, McGilvray M, McNamara L, 
Breakwell L, Yu Y, Bhavsar T, Briere E, Patel M. Safety of a meningococcal group B vacci ne 
used in response to two university outbreaks. J Am Coll Health. 2017;65(6):380-8. Epub 2017/04/01. doi: 10.1080/07448481.2017.1312418. PubMed PMID: 28362241; PMCID: PMC6574050. 
DMID Protocol 19- [ADDRESS_521410]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521411] use of an 
investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7(6):646-53. Epub 2011/09/10. doi: 10.4161/hv.7.6.[ZIP_CODE]. PubMed PMID: 21904120. 
18. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of 
a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483-6. Epub 2010/12/24. doi: 10.1128/CVI.[ZIP_CODE]-10. PubMed PMID: 21177912; PMCID: PMC3067382. 
19. Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and 
immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322-30. Epub 2015/05/31. doi: 10.1016/j.vaccine.2015.05.027. PubMed PMID: 26025807. 
20. Hong E, Terrade A, Taha MK. Immunogenicity and safety among laboratory workers 
vaccinated with Bexsero(R) vaccine. Hum Vaccin Immunother. 2017;13(3):645-8. Epub 2016/11/04. doi: 10.1080/21645515.2016.1241358. PubMed PMID: 27808594; PMCID: PMC5360120. 
21. American Society for Gastrointestinal E, Ikenberry SO, Anderson MA, Banerjee S, 
Baron TH, Dominitz JA, Gan SI, Harrison ME, Jagannath S, Levy M, Lichtenstein D, Shen B, Fanelli RD, Stewart L, Khan K. Endoscopy by [CONTACT_102876]. Gastrointest Endosc. 2009;69(4):767-70. doi: 10.1016/j.gie.2008.11.006. PubMed PMID: 19327469. 
22. Society of Gastroenterology Nurses and Associates Inc. Guideline for Performance of 
Flexible Sigmoidoscopy by [CONTACT_413669] 2009. 
23. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of 
perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95(3):230-6. doi: 10.1093/jnci/95.3.230. PubMed PMID: 12569145. 
24. Levin  TR, Conell C, Shapi[INVESTIGATOR_179733], Chazan SG, Nadel MR, Selby [CONTACT_9715]. Complications of 
screening flexible sigmoidoscopy. Gastroenterology. 2002;123(6):1786-92. doi: 
10.1053/gast.2002.[ZIP_CODE]. PubMed PMID: 12454834. 
DMID Protocol 19- [ADDRESS_521412]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      98 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  25. Koobatian GJ, Choi PM. Safety of surveillance colonoscopy in long-standing ulcerative 
colitis. Am J Gastroenterol. 1994;89(9):1472-5. PubMed PMID: 8079922. 
26. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams 
CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030-8. doi: 10.1053/j.gastro.2005.12.035. PubMed PMID: 16618396. 
27. Yao MD, von Rosenvinge EC, Groden C, Mannon PJ. Multiple endoscopic biopsies in 
research su bjects: safety results from a National Institutes of Health series. Gastrointest Endosc. 
2009;69(4):906-10. doi: 10.1016/j.gie.2008.05.015. PubMed PMID: 19136110; PMCID: PMC5050003. 
28. Chiu WK, Brand RM, Camp D, Edick S, Mitchell C, Karas S, Zehmisch A, Ho K, Brand 
RE, Harrison J, Abo S, Cranston RD, McGowan I. The Safety of Multiple Flexible Sigmoidoscopi[INVESTIGATOR_413623]. AIDS Res Hum Retroviruses. 2017;33(8):820-6. doi: 10.1089/aid.2016.0293. PubMed PMID: 28296471; PMCID: PMC5564058. 
 
  
DMID Protocol 19- [ADDRESS_521413]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521414]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      100 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018   Appendix A. SCHEDULE OF EVENTS  
Procedures  
Screening (Visit 00A)  
Day -56 to - 1 (-56 to - 28 
for biopsy cohort)  
Screening (Visit 00B)  
Day -7 to -1 ( -34 to -28 
for biopsy cohort)  
Baseline Rectal Mucosal 
Biopsy , Visit 00C, Day -
28 to - 14 
Study Visit 00P (Phone 
visit) , Day -27 to - 12 
Enrollment/Baseline  
Visit 1, Day 1  
 Study Visit 2  
Day 8 ± 1 day  
Study Visit 3  
Day 15 ± 1 days  
Study Visit 4e 
Day 29 ± 1 days  
Study Visit 5  
Day 36 ± 1 days  
Study Visit 6f 
Day 43 ± 3 days  
Study Visit 6P (Phone 
visit)  
Day 44 + 1 days  
Study Visit 7  
Day 57 ± 1 days  
Final Study Visit 8  
Day 181 ±  7 days  
Early Termination Visit  
Informed consent  X              
Assessment of Eligibility Criteria  X X   X          
Demographics  X              
Medical history  X---------------------------------------- X  X----------------------------------------------------------------- X  X--------------------- X X 
Sexual history  X X X  X   X  X  X X X 
Randomization      X          
Concomitant medication review  X---------------------------------------- X  X----------------------------------------------------------------- X  X--------------------- X X 
Review COVID -19 vaccine 
history    X   X      
Vital signs  X (X) X  X (X) (X) X (X) X  (X) (X) (X) 
Physical exam  X (X) (X)  (X)-------------------------------------------------------------------------------------------------------- (X) (X) 
Administer study intervention      X   Xe       
DMID Protocol 19- [ADDRESS_521415]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      101 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Procedures  
Screening (Visit 00A)  
Day -56 to - 1 (-56 to - 28 
for biopsy cohort)  
Screening (Visit 00B)  
Day -7 to -1 ( -34 to -28 
for biopsy cohort)  
Baseline Rectal Mucosal 
Biopsy , Visit 00C, Day -
28 to - 14 
Study Visit 00P (Phone 
visit) , Day -27 to - 12 
Enrollment/Baseline  
Visit 1, Day 1  
 Study Visit 2  
Day 8 ± 1 day  
Study Visit 3  
Day 15 ± 1 days  
Study Visit 4e 
Day 29 ± 1 days  
Study Visit 5  
Day 36 ± 1 days  
Study Visit 6f 
Day 43 ± 3 days  
Study Visit 6P (Phone 
visit)  
Day 44 + 1 days  
Study Visit 7  
Day 57 ± 1 days  
Final Study Visit 8  
Day 181 ±  [ADDRESS_521416]-vaccination Observation 
(for ≥15 minutes) to Assess 
Acute Reactions      X   X       
Evaluation of Vaccination Site to 
Assess for Reactogenicity and AE/SAEs after ≥15 minutes      X   X       
Memory Aid      X X  X X     (X) 
Adverse event review and 
evaluation    Xd Xd X-----------------------------------------------------------------X Xd X-------------------X X 
Sampling procedures  
Hematology  (CBC, PT, aPTT)a X (X) (X)            
Urine pregnancy test  X (X)   X   X      (X) 
STI screeningb Xc    (X)------------------------- (X) X (X)------------ (X)  (X) X  
Rectal mucosal biopsya   X       Xf     
DMID Protocol 19- [ADDRESS_521417]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      102 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Procedures  
Screening (Visit 00A)  
Day -56 to - 1 (-56 to - 28 
for biopsy cohort)  
Screening (Visit 00B)  
Day -7 to -1 ( -34 to -28 
for biopsy cohort)  
Baseline Rectal Mucosal 
Biopsy , Visit 00C, Day -
28 to - 14 
Study Visit 00P (Phone 
visit) , Day -27 to - 12 
Enrollment/Baseline  
Visit 1, Day 1  
 Study Visit 2  
Day 8 ± 1 day  
Study Visit 3  
Day 15 ± 1 days  
Study Visit 4e 
Day 29 ± 1 days  
Study Visit 5  
Day 36 ± 1 days  
Study Visit 6f 
Day 43 ± 3 days  
Study Visit 6P (Phone 
visit)  
Day 44 + 1 days  
Study Visit 7  
Day 57 ± 1 days  
Final Study Visit 8  
Day 181 ±  7 days  
Early Termination Visit  
Vaginal secretion sampling      X   X  X  X X (X) 
Rectal secretion sampling      X   X  X  X X (X) 
Oropharyngeal secretion 
sampling      X   X  X  X X (X) 
Blood draw for serum antibody 
assays      X   X  X  X X (X) 
Blood draw for systemic 
immunity assays      X X X X X X  X X (X) 
aOnly to be performed in the rectal mucosal biopsy cohort ( approximate N=20) 
bSTI screening will include GC/CT NAAT of urine, pharynx, and rectum, and RPR. HIV antibody testing will occur at Visit 00A and 08 only 
cBaseline STI screening in non -pregnant females will also include NAAT for Trichomonas  
dAE review and evaluation at Visit 00C  will include only AEs from the baseline biopsy procedure  
e The following will be reviewed for safety prior to administering the second dose: interim medical history, concomitant medications, COVID -[ADDRESS_521418] result for females of childbearing potential.  
f The following will be reviewed for safety prior to the rectal mucosal biopsy procedure: interim medical history, concomitant medications,  and vital signs.  
DMID Protocol 19- [ADDRESS_521419]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      103 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Procedures  
Screening (Visit 00A)  
Day -56 to - 1 (-56 to - 28 
for biopsy cohort)  
Screening (Visit 00B)  
Day -7 to -1 ( -34 to -28 
for biopsy cohort)  
Baseline Rectal Mucosal 
Biopsy , Visit 00C, Day -
28 to - 14 
Study Visit 00P (Phone 
visit) , Day -27 to - 12 
Enrollment/Baseline  
Visit 1, Day 1  
 Study Visit 2  
Day 8 ± 1 day  
Study Visit 3  
Day 15 ± 1 days  
Study Visit 4e 
Day 29 ± 1 days  
Study Visit 5  
Day 36 ± 1 days  
Study Visit 6f 
Day 43 ± 3 days  
Study Visit 6P (Phone 
visit)  
Day 44 + 1 days  
Study Visit 7  
Day 57 ± 1 days  
Final Study Visit 8  
Day 181 ±  7 days  
Early Termination Visit  
Abbreviations: X, study procedure for all participants; (X), study procedures to be determined by [CONTACT_464]; CBC, complete blood count; PT, prothrombin time; aPTT, activated partial 
thromboplastin time; STI, sexually transmitted infection  
 
  
DMID Protocol 19- [ADDRESS_521420]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521421] screen  
(V00A)  2nd screen  
(V00B)  V00Ca V1 V2 V3 V4 V5 V6 V7 V8 
Study Day relative 
to Vaccination #1 
(D1)   D-56 to -1 
(D-56 to -28 for 
rectal biopsy 
cohort)  D-7 to -1 
(D-34 to -28 for 
rectal biopsy 
cohort)  -28 to  -
14 1 8 15 29 36 43 57 181 
Sampling Procedures  (blood volumes in mL)  
Clinical Laboratory  Screening serology (RPR)  8  
    8    
8 
Hematology (CBC)a 4 4          
Coagulation testing (PT/aPTT)a 4 4          
GC/CT NAAT x3 mucosal sites  X  
    X  Xb  X 
Trichomonas NAAT  Xc           
 
Mucosal Immunity  Rectal mucosal IgG against Ng 
antigens     X   X  X X X 
Vaginal mucosal IgG against Ng 
antigens     X   X  X X X 
DMID Protocol 19- [ADDRESS_521422]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521423] screen  
(V00A)  2nd screen  
(V00B)  V00Ca V1 V2 V3 V4 V5 V6 V7 V8 
Study Day relative 
to Vaccination #1 
(D1)   D-56 to -1 
(D-56 to -28 for 
rectal biopsy 
cohort)  D-7 to -1 
(D-34 to -28 for 
rectal biopsy 
cohort)  -[ADDRESS_521424] 
Ng antigens     X   X  X X X 
Rectal mucosal T cell phenotypi[INVESTIGATOR_007] 
(ICS)a   X      X   
 
Systemic Immunity  Serum IgG against Ng antigens 
(ELISA)     [ADDRESS_521425] Ng antigens 
(ELISA)     8   8  8 8 8 
Ng specific MBC (ELISPOT)     24   24  24  24 
Ng specific T cell (ELISPOT)     [ADDRESS_521426]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      [ADDRESS_521427] screen  
(V00A)  2nd screen  
(V00B)  V00Ca V1 V2 V3 V4 V5 V6 V7 V8 
Study Day relative 
to Vaccination #1 
(D1)   D-56 to -1 
(D-56 to -28 for 
rectal biopsy 
cohort)  D-7 to -1 
(D-34 to -28 for 
rectal biopsy 
cohort)  -28 to  -
14 1 8 15 29 36 43 57 181 
OMV and peptide antigen specific T 
cell (ICS)     [ADDRESS_521428] Nm antigens 
(ELISA)     8     8  8 
Nm specific MBC (ELISPOT)     16   16  16   
Nm specific T cell (ELISPOT)     16  16   16   
Blood volumes (mL)  
Per visit   16 8 0 136 16 64 112 16 136 72 56 
Cumulative   16 24 24 160 176 240 352 368 504 576 632 
aOnly for subjects in the rectal mucosal biopsy cohort 
bOnly if indicated based on interim sexual history 
cFemale subjects only 
Abbreviations : Ng, Neisseria gonorrhoeae; Nm, Neisseria meningitidis 
DMID Protocol 19- [ADDRESS_521429]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      107 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018   Appendix C. TOXICITY TABLE  
Local (Injection Site) Reactogenicity Grading  
Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the 
injection site 
(spontaneous discomfort)  Subject is aware of pain, 
but it does not interfere 
with daily activity,  and it 
does not require  pain 
medication or it requires 
use of a non- narcotic pain 
reliever ≤24hours  Subject is aware of pain; 
there is interference with 
daily activity  or it 
requires repeated use of a 
non-narcotic pain reliever 
for >[ADDRESS_521430] is aware of pain, 
and it prevents daily 
activity or requires any use 
of a narcotic pain reliever  
Tenderness – hurts only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
interferes with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Pruritus (Itching)  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness)/Swelling*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
* Size will also be measured in mm but will not be used as a halting criterion.  
 
Ecchymosis (bruising), erythema (redness), and induration (hardness)/swelling as analyzed by 
[CONTACT_319679]: 
DMID Protocol 19- [ADDRESS_521431]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      108 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018   
Local (Injection Site) Reactogenicity Measurements  
Local (Injection Site) Reaction  Mild (Grade 1)  Moder ate (Grade 2)  Severe (Grade 3)  
Ecchymosis (Bruising)*  25 mm – 50 mm 51 mm – 100 mm  >100 mm 
Erythema (Redness)*  25 mm – 50 mm 51 mm – 100 mm >100 mm 
Induration (Hardness)/Swelling*  25 mm – 50 mm 51 mm – 100 mm >100 mm 
* Will not be used as halting criteria.  
Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(Chills/Shivering/Sweating)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Fatigue (Tiredness)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Malaise (General Unwell 
Feeling)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference , 
prevents daily activity  
Arthralgia (Joint Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Headache  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Nausea No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
* Not at injection site.  
DMID Protocol 19- [ADDRESS_521432]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      109 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018   
Oral temperature# will be graded as follows: 
Quantitative Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 38.0°C – 38.4°C  
100.4°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature assessed on Day [ADDRESS_521433] study vaccination will be considered as 
baseline.  
* A fever can be considered not related to the vaccine if an alternative etiology can be 
documented. 
† Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking 
oral temperature.  
 
 
 
Additional Adverse Event Severity Grading  
Pulse and blood pressure# will be graded as follows: 
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute 50 – 54 45 – 49 <45 
Tachycardia - beats per minute  101 – 115 116 – 130 >130 
Hypotension (systolic) mmHg  85 – 89 80 – 84 <80 
Hypotension (diastolic) mmHg 50 – 54 45 – 49 <45 
Hypertension (systolic) mmHg 141 – 150 151 – 155 >[ADDRESS_521434]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      110 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Hypertension (diastolic) mmHg 91 – 95 96 – 100 >100 
# Pulse and blood pressure assessed on Day [ADDRESS_521435]  2023 
 ______________________________________________________________________________________________________  
 
 
DMID/NIAID/NIH    CONFIDENTIAL      111 
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Clinical safety laboratory results * will be graded as follows: 
Clinical Safety Laboratory Adverse Event*  
Hematology  Normal Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC 103/µL ( Low) 3.8 – 10.8 2.5 – 3.7 1.5 – 2.4 <1.5 
WBC 103/µL ( High ) 3.8 – 10.8 10.9 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL ( Low) (Female)  11.7 – 15.5 11.0 – 11.6 9.5 – 10.9 <9.5 
Hgb g/dL ( Low) (Male)  13.2 – 17.1 12.0 – 13.1 10.0 – 11 .9 <10.0 
Platelets 103/µL ( Low) 140 – 400 125 – 139 100 – 124 <100  
Platelets 103/µL ( High ) 140 – 400 401 – 550 551– 750 >750  
PT (seconds) (increase by [CONTACT_12245] ) 
(prothrombin time)  9.0 – 11.5 >1.0 – 1.[ADDRESS_521436]  >1.1 – 1.[ADDRESS_521437]  > 1.[ADDRESS_521438]  
aPTT (seconds) (increase by [CONTACT_12245]) 
(activated partial thromboplastin 
time)  22.0 – 34.0 
>1.0 – 1.[ADDRESS_521439]  >1.2 – 1.[ADDRESS_521440]  >1.[ADDRESS_521441]  
 
*Clinical laboratory evaluations assessed at the screening visit will be considered as baseline 
 
 